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Abstract 
Purpose. Negative symptoms in schizophrenia have a significant impact on 
recovery. There has been increased reporting in the literature on the benefits of 
psychosocial interventions for these symptoms. However, thus far no attempt 
has been made to disentangle the effective components of these interventions 
and the specific negative symptoms they target. This review aimed to address this 
need by systematically reviewing the literature utilising narrative synthesis 
techniques.  
Methods. A literature search of electronic databases, reference lists and forward 
citations, and a hand search of Clinical Psychology Review and Schizophrenia 
Research was completed with authors contacted for unpublished data and/or 
further related work. Thematic analysis techniques were employed to extricate 
common psychosocial components from interventions.   
Results. Eleven articles met inclusion criteria with all reporting reduction rates 
in specific negative symptoms. Avolition was the most common target of 
interventions. There is marked variance in methodologies employed across the 
included papers with various theoretical frameworks guiding intervention. 
Descriptions of psychosocial interventions in papers are not sufficient to allow 
for clear understanding of the components of interventions that target specific 
symptoms. Common themes of treatment components were identified. 
Conclusions. The review is the first of its kind in attempting to define and 
synthesise effective psychosocial intervention components and the specific 
negative symptoms they target. The reviewed interventions report positive 
effects on negative symptoms but there is marked variance in methodologies. 
The implications of this variance are discussed and future avenues of research 
identified.  
 
Practitioner points 
 The psychosocial approach to treating negative symptoms is an emergent 
field of research indicating beneficial effects. 
 There is a need to develop a unified approach to research in this field.  
 Avolition is amenable to psychosocial intervention, consistent with 
research outcomes. 
 Common intervention components are identified which may guide clinical 
intervention strategies.  
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Introduction 
People diagnosed with schizophrenia experience symptoms classified as positive, 
those that are abnormal by virtue of their presence, and negative, those which 
reflect a loss or diminution of a previously present capacity (Carpenter, 
Heinrichs, & Wagman, 1988). Negative symptoms in schizophrenia are 
characterised by a lack of motivation, reduced capacity for enjoyment and 
engagement in everyday activities. Up to 40% of individuals with chronic 
schizophrenia can experience negative symptoms (an der Heiden, Leber, & 
Hafner, 2016).  
There remains a gap in knowledge about effective treatments for negative 
symptoms and there is significant variability in current approaches, highlighted 
recently in a systematic review by Elis, Caponigro and Kring (2013). It is 
important to understand how change is brought about through a given 
intervention, specifically what the mechanisms of change may be for negative 
symptoms (Kaiser, Lyne, Agartz, Clarke, Morch-Johnsen, & Faerden, 2016). Elis 
et al (2013) described a variety of psychosocial interventions and their influence 
on negative symptom outcomes. It is unclear what the effective mechanisms of 
psychosocial interventions are and what specific negative symptoms they target, 
factors which the Medical Research Council (MRC) indicate are important in 
intervention development (Craig, Dieppe, Macintyre, Michie, Nazareth, & 
Petticrew, 2008). This is also important for understanding the long-term effects 
of treatments and may aid in adapting interventions to meet individual need 
(Chien, Leung, Yeung, & Wong, 2013).  
The evolution of negative symptom conceptualisation may be a contributing 
factor to the noted variance in psychosocial intervention/outcomes. Recent 
views suggest  negative symptoms can be meaningfully subdivided into 
expressive and experiential deficits (Foussias & Remington, 2010; Foussias, Agid, 
Fervaha, & Remington, 2014). Kaiser et al (2016) highlight an issue in the ways 
in which these subdomains are defined across the literature (i.e. ‘avolition’ being 
used interchangeably as a ‘symptom’ or a blanket term for other symptoms). 
Conceptualising negative symptoms is further complicated by primary and 
secondary symptoms. Kirschner, Aleman, and Kaiser (2016) recently indicated 
the need for assessment and treatment of symptoms intrinsic to schizophrenia 
(primary) and those stemming from other influences (secondary). Secondary 
symptoms may emerge through the impact of positive symptoms, comorbid 
mental health disorders (e.g. depression), or through medication side effects. It 
is possible that the mechanisms underlying the development and/or 
maintenance of specific negative symptoms may vary (Kirschner et al, 2016) and 
this will have implications for identifying mechanisms of therapeutic effect. For 
example, social skills training (SST) may improve social skill deficits but not 
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cognitive impairment. Therefore, understanding specific intervention 
mechanisms may aid in matching treatment to symptoms. 
Finally, Moritz, Berna, Jaeger, Westermann, & Nagel (2016) recently highlighted 
the variance in treatment outcome priorities between patients, carers, and 
professionals. This can make measurement of intervention ‘success’ difficult. For 
example, Schooler et al's (2015) consensus statement provides clinical guidelines 
on what constitutes acceptable recovery indicators. Yet, this notion of recovery 
may be at odds with what people who experience schizophrenia find acceptable 
from interventions (Sterk, Winter van Rossum, Muis, & de Haan, 2013). 
Additionally, no systematic attempt has thus far been made to extricate 
treatment effects in relation to negative symptom subdomains (Galderisi, Farden, 
& Kaiser, 2016).  It is therefore crucial to address this gap and to understand what 
negative symptom interventions are currently acceptable.   
Objective 
To analyse psychological treatment studies and extract descriptions of effective 
psychosocial treatment techniques that target specific negative symptoms. The 
following questions guided the systematic review: 
1. What psychosocial treatment techniques have proven effective in the 
treatment of specific negative symptoms and how are they described in 
the literature? 
 
2. What specific negative symptoms do these techniques improve and how 
are improvements measured? 
 
3. How acceptable are the interventions and the associated outcomes to 
patients?  
 
Methods  
 
A systematic review of the literature was completed in accordance with the 
PRISMA statement (Moher, Liberatti, Tetzlaff, & Altman, 2009). The following 
inclusion and exclusion criteria were applied.  
Inclusion criteria: 
 Adult participants (aged 18-65) with a reported diagnosis of a 
Schizophrenia Spectrum Disorder (SSD).  
 Provides descriptions of psychosocial interventions for the treatment of 
negative symptoms. 
 Mixed methodologies, including meta-analyses and systematic reviews.  
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 Primary or secondary clinical outcomes for specific subdomains of 
negative symptoms.  
Exclusion criteria: 
 Non-psychosocial interventions (e.g. solely drug studies).  
 Clinical guidelines, conference/presentations, editorials, theoretical 
papers, book chapters, and grey literature.  
 Papers not written in English.   
Search Strategy 
The literature search, carried out in August 2015, consisted of a mixture of both 
electronic and hand searching of resources. The following online databases were 
searched up to August 2015: EBSCO - CINAHL, MEDLINE PyschINFO, and 
Psychological and Behavioural Sciences Collection; Ovid – Journals@Ovidfulltext. 
NHS Scotland Journals, Ovid Medline, and Embase; and NCBI – PubMed. 
For each of the databases two groups of terms were applied. Group one consisted 
of a broad set of terms related to psychosocial interventions (e.g. “psychosocial 
interventions”… “Psychosocial therapy”) and a narrow set of terms (e.g. 
“cognitive therapy”), which were then grouped together using the Boolean 
operator “OR”. Group two consisted of a broad set of terms related to 
schizophrenia and negative symptoms (e.g. “schizophrenia…psychosis”) and a 
narrow set of terms (e.g. “alogia, anhedonia, apathy”), which were then grouped 
together using the Boolean operator “OR”. These two groups were combined 
using the Boolean operator “AND” to perform the search. Three authors were 
contacted for original papers where items were electronically inaccessible, all 
responded.  
To identify further relevant articles that the electronic search may have 
overlooked, forward citation of two key papers (Elis et al, 2013; Schooler et al, 
2015) and a hand search of their reference list was carried out by one author 
(PS). An additional hand search of two journals (Clinical Psychology Review and 
Schizophrenia Research) was conducted. This stage of the search identified a 
combined total of 1,392 papers for initial screening.  
Screening 
A small sample of titles and abstracts were independently screened by two 
authors (HM and PS) as part of eligibility screening to ensure the 
inclusion/exclusion criteria were sufficient and to minimise bias. A concordance 
rate of 80% was achieved with disagreements resolved by discussion as per 
predefined strategy in the review protocol. The eligibility criteria were applied 
to all titles and abstracts which led to 1,047 papers being excluded.  
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Full screening of 182 papers was completed, leading to 173 papers being 
rejected. Nine papers were identified for inclusion and a hand search of each 
reference list was completed. Furthermore, the authors of these nine included 
papers were contacted to enquire for further data (both published and 
unpublished). This led to an additional two papers identified for inclusion, 
providing a final total of 11 included papers (see Figure 1).  
Data extraction and synthesis 
The characteristics of participants, methodologies applied, and interventions 
used within the included studies varied. Popay et al (2006) provide guidance on 
conducting a narrative-synthesis approach to tackle this issue of heterogeneity 
when assessing the effects of interventions from research evidence. The 
synthesis can include the following phases: 
 Developing a preliminary synthesis of findings of included studies. 
 Exploring relationships in the data.  
 Assessing the robustness of the synthesis.  
This approach was adopted within this review and utilised further techniques 
described by Arai et al (2007). Thematic analysis was adapted from strategies 
reported elsewhere in the literature (see Bird, Boutillier, Leamy, Williams, 
Bradstreet & Slade, 2014). The extraction and synthesis of data was carried out 
in a number of stages, described below. 
Stage One – Data extraction, tabulation, and quality rating 
The sources of data were heterogeneous in nature (i.e. a mixture of both 
quantitative and qualitative studies with mixed methodologies). The first step 
included extracting information from each study for quality rating (see Table 1). 
This information was then transformed into a tabulated format providing 
descriptions of key factors relevant to the review objective (see Tables 2 and 3 
below). 
Following this, the psychosocial intervention, described in each paper, was 
analysed by one author (PS). These were diluted into single coded components 
to identify the specific technique being described.  
Stage Two – Exploring relationships between studies 
Intervention descriptions, outcome measurement, and negative symptom 
outcome were explored to identify relationships between studies in relation to 
the objectives of the study.  
Stage Three – Thematic analysis 
Thematic analysis (Braun & Clarke, 2006) was used as a framework and applied 
to the psychosocial components identified in Stage One. The coded psychosocial 
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components were cross referenced by one author (HM) for triangulation. For 
example, enhancing the ability to take the perspective of others was coded 
’developing skills to understand and respond in social situations’ and coping with 
stressors was coded as ‘’developing skills to meet challenges’.  Further similar 
codes, within and across studies, were collated and formed the broad theme of 
‘developing generic problem solving skills that enable people to understand and 
respond to everyday challenges’. Themes were then vote counted across all the 
studies.  A decision was made a priori that themes would be included should they 
occur in at least five or more of the 11 included studies.  
Quality Rating 
Papers were appraised for quality by one author (PS) and an independent rater 
using the Crowe Critical Appraisal Tool (CCAT; Crowe and Shepperd, 2011). This 
tool can be used across research designs and provides a comprehensive user 
guide which can aid inter-rater reliability (Crowe, Sheppard, & Campbell, 2012). 
The CCAT is comprised of 8 sub-categories and a total quality score.  A threshold 
was set a priori indicating no more than a difference of 3 points on a 40 point 
scale for agreement in quality. Seven of the included studies reached this level of 
agreement and the range of discrepancy on the other papers ranged from 5 to 7. 
Discrepancies were resolved by discussion and a consensus score reached (see 
Table 1).  
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Table 1 - CCAT Quality Appraisal Scores 
Study Total 
(Max
=40) 
% 
Scor
e 
Preamble Intro Design Sample Data Ethics Results Disc 
Eack, Mesholam-
Gately, 
Greenwald, 
Hogarty, & 
Keshavan 
(2013) 
26 65 3 3 3 2 4 2 5 4 
Favrod, Giuliani, 
Ernst & Bonsack 
(2010) 
22 55 3 5 2 1 2 1 3 4 
Favrod et al, 
(2015) 
30 75 5 5 3 3 3 4 4 3 
Granholm, 
Holden, Link & 
McQuaid (2014) 
35 88 5 5 5 3 4 4 4 5 
Grant, Huh, 
Perivoliotis, 
Stolar,& Beck 
(2012) 
32 80 4 2 5 4 5 4 4 4 
Johns, Sellwood, 
McGovern & 
Haddock’s 
(2002) 
22 55 4 3 2 2 3 2 4 2 
Johnson, Penn, 
Fredrickson, & 
Meyer Kring & 
Brantley, (2009) 
10 25 3 3 1 0 1 0 1 1 
Johnson et al 
(2011) 
24 60 2 5 3 2 2 4 4 2 
Klingberg et al 
(2011) 
37 93 5 5 5 5 4 5 4 4 
Rohricht & 
Priebe, (2006) 
34 85 5 3 4 4 4 5 5 4 
Röhricht,Papado
poulos,  Holden, 
Clarke, Priebe, 
(2011) 
29 73 5 4 4 3 3 3 3 4 
 
Results 
Figure 1 highlights the flow diagram for the process and selection of the final 
eleven included studies. See Appendix 1.2 for examples of excluded studies with 
reason for exclusion. Results are presented below in relation to the three review 
objectives. 
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Figure 1: Flow Diagram of Study Selection  
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Objective 1: What psychosocial treatment techniques have proven effective in the 
treatment of specific negative symptoms and how are they described in the 
literature? 
The included papers, which dated from 2002 to 2015, present a variety of 
methodologies, interventions, therapeutic targets, and outcomes. Table 2 
highlights the reported outcomes from each study.  All studies reported positive 
effects on negative symptoms yet some studies did not report effects that were 
statistically significant. The included interventions can be generally grouped into 
two categories: cognitive-behavioural interventions and integrative therapies. A 
brief description of commonalities across each group is provided below before 
focusing on treatment techniques.   
  
16 
 
Table 2: Treatment Targets and Outcomes 
Study Treatment Target Outcome Measure* Negative Symptom Outcome 
Eack et 
al. 2013 
Social and non-social 
cognition. 
 
WNSS / BPRS 
 
 CET group - Overall 2 year improvement in negative 
symptoms (significant and medium effect size). 
Analysis of differential effects of CET on negative 
symptom domains indicated improvements in social 
withdrawal (d = 1.08), motor retardation (d = 0.63), 
and affect flattening (d = 0.68).  
Favrod et 
al 2010 
Anhedonia Primary - TEPS/ TBM 
Secondary - CDSS.  
All participants had significant clinical change in 
anticipatory pleasure.  They showed an increase in 
the number of activities as well as in the complexity 
of these activities. 
Favrod et 
al 2015 
Anhedonia and apathy.  SANS/ CDSS/ SBI 
 
Significant reduction of symptoms. Cohen's d ES= 
0.50 for Anhedonia-Asociality and 0.57 for the 
Avolition- Apathy. Moderate overall effect size.  
Granholm 
et al 2014 
Amotivation/asociality and 
self-efficacy.  
Primary measure: ILSS. 
Secondary measures: 
CMT/ MASC/ PSR/ 
PANSS/ SANS/ BDI-II/ 
DPAS 
Significant improvement over time for functioning, 
negative symptoms, defeatist attitudes and skill 
knowledge related to CBSST. Positive effects for 
CBSST noted in the reduction in scores for 
diminished motivation and diminished expression.  
 
Grant et 
al 2012 
Global functioning and 
negative symptoms.  
Primary – GAS 
Secondary - Subscales of 
SANS/ Total of SAPS 
 
CT group showed significantly greater improvement 
in global functioning and significant reduction in 
Avolition-Apathy.  
Johns et 
al 2002 
Avolition/apathy: targeted 
both objective (levels of 
activity) and subjective 
(associated distress).  
Primary: SANS/ SENS 
Secondary: CDSS/ 
LUNSERS 
 
No significant difference in total scores for negative 
symptoms.  However, there was a significant 
reduction in avolition scores for three of the four 
participants. 
Johnson 
et al 2009 
Three individual case studies 
each experiencing different 
negative symptoms 
 
Not specified.  Two cases reported improvements in negative 
symptoms.  
Johnson 
et al 2011 
Anhedonia, avolition, and 
asociality, 
mDES/ CAINS/ 
TEPS/Psychological 
recovery measured using 
specific subscales from 
SPWB/ THS/ SWLS  
Substantial improvements in frequency and 
intensity of positive emotions at post-treatment and 
3-month follow up. Large decrease in total negative 
symptoms and anhedonia (large effect size) as well 
as asociality (medium effect size) at post-treatment 
and 3-month follow-up, Analyses of consummatory 
pleasure yielded a large positive effect size at post-
treatment. Environmental mastery, self-acceptance, 
and satisfaction with life all improved.  
Klingberg 
et al 2011 
Defeatist beliefs. Socio-
cognitive skills (emotion 
detection/expression) 
 
Primary –PANSS 
 
Secondary -  Standard 
scale of PANSS/ SANS 
 
No significant difference of negative symptoms 
between CBT group and CR group. However, CBT 
group reduced scores for each SANS subscale and 
for total score (non-significant). 
Rohricht 
& Priebe, 
2006. 
Emotional 
withdrawal/affective blunting 
and motor retardation. 
Primary - negative 
subscale of PANSS. 
 
Secondary -  EPS/ SQOL/ 
MANSA/ CAT/ HAS 
BPT group had significantly lower PANSS negative 
symptom scores than SC group after treatment. Also, 
BPT group experienced significant reductions in 
negative symptoms of blunted affect and motor 
retardation. No variation between groups in other 
measures of psychopathology.  
Röhricht 
et al 2011 
Emotional 
withdrawal/affective blunting 
and motor retardation. 
Primary - Sub-scale 
“negative” on PANSS/ 
Subscale “anergia” on 
BPRS. 
Secondary – PANSS/ 
MANSA/ SFS 
Significant reduction in PANNS negative scale 
scores.  Significant reduction in negative symptoms 
of anergia and flat affect (BPRS).  
 
 
* BDI-II –Beck Depression Inventory, BPRS - Brief Psychiatric Rating Scale, BPT – Body-orientated Psychotherapy, CAINS - Clinical Assessment Interview for 
Negative Symptoms, CAT – Client’s Assessment of Treatment, CBSST – Cognitive Behavioural Social Skills Training, CDSS –Calgary Depression Scale for 
Schizophrenia, CET – Cognitive Enhancement Therapy, CMT - Comprehensive Module Test, CR- Cognitive Remediation Therapy, CT –Cognitive Therapy, d – 
Cohen’s d, DPAS - Defeatist Performance Attitude Scale, DES-IV – Differential Emotions Scale, EPS - Extrapyramidal Symptom Scale, GAS - Global Assessment Scale, 
HAS – Helping Alliance Scale, ILSS - Independent Living Skills Survey, LUNSERS – Liverpool University Neuroleptics Side Effects Ratings Scale, MANSA – 
Manchester Short Assessment of Quality of Life, MASC - Maryland Assessment of Social Competence, mDES - Modified Differential Emotions Scale, PANSS - Positive 
and Negative Syndrome Scale, PSR - Psychosocial Rehabilitation Toolkit, SANS - Scale for the Assessment of Negative Symptoms, SANS - Scale for the Assessment 
of Negative Symptoms, SAPS - Scale for the Assessment of Positive Symptoms, SBI - Savoring Belief Inventory, SC- Supportive Counselling, SENS,- Subjective 
Experience of Negative Symptoms Scale, SFS – Social Functioning Scale, SQOL – Subjective Quality of Life, SWLS – Satisfaction with Life Scale, SWPB – Scales of 
Psychological Well Being, TBM - Time Budget Measure, TEPS - Temporal Experience of Pleasure Scale, THS –Trait Hope Scale, WNSS - Wing Negative Symptom 
Scale  
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Cognitive-Behavioural Interventions 
Five studies utilised elements of cognitive behavioural therapy (CBT) with 
variance in their application across each study (Favrod et al, 2010; Favrod et al, 
2015; Grant et al, 2012; Johns et al, 2002; Klingberg et al, 2011). Three studies 
also employed traditional concepts from CBT including individual case 
formulation, collaboration, and developing a therapeutic relationship (Grant et 
al, 2012; Johns et al, 2002; Klingberg, 2011).  
Cognitive Components  
Two interventions (Favrod et al, 2010; Favrod et al, 2015) place substantial 
emphasis on different cognitive processes in targeting negative symptoms. The 
cognitive-sensory intervention for severe anhedonia described by Favrod et al 
(2010) focused on cognitive skills development (e.g. imagining images, emotional 
experiences, and memory recall). However, in the Positive Emotions Program for 
Schizophrenia (PEPS; Favrod et al, 2015), which also targets anhedonia and 
apathy, the focus is on cognitive control of positive emotions. PEPS aims to 
enhance this through challenging defeatist beliefs and also in developing skills in 
anticipating and maintaining positive emotions. 
The salient role of defeatist beliefs in the maintenance of negative symptoms was 
a major concept in three studies (Favrod et al, 2015; Grant et al, 2012; Klingberg 
et al, 2011). These studies indicate that challenging defeatist beliefs is an 
important component in treatment. Johns et al (2002) also incorporate negative 
thought challenging within the study description but it is unclear which specific 
thoughts were targeted.  
Behavioural (Skills) Components  
Grant et al’s (2012) CBT intervention placed a significant emphasis on skills 
based activities during treatment in line with their goal focused outcomes. 
Several activities (e.g. role play and community trips) were utilised to develop 
skills that would help people increase their daily functioning skills. Klingberg et 
al (2011) had a similar substantial focus on skills development with modules 
targeting individual negative symptoms through techniques such as social 
activity and emotional participation and expression.  The PEPS (Favrod et al, 
2015) incorporates skills practice in each session which can include both 
cognitive elements (e.g. imagining exercises) or behavioural strategies (e.g. 
learning how to express positive emotions through behavioural expression).  
Johns et al (2002) indicate that behavioural goals are an integral part of their 
treatment but no further specific information is provided. Favrod et al (2010) 
focus heavily on cognitive processes and state behavioural skills are practiced 
once the cognitive skills have developed (i.e. completing a daily living activity as 
homework).  
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Integrative Therapies  
Two studies rely on the amalgamation of different therapeutic interventions to 
target negative symptoms. Cognitive Enhancement Therapy (CET; Eack et al, 
2013) incorporates a substantial repertoire of computer-based cognitive training 
that is then enhanced by peer group therapy. CET was not intended as a specific 
treatment for negative symptoms with post hoc analysis revealing positive 
effects. 
Granholm et al (2014) describe Cognitive Behavioural Social Skills Training 
(CBSST), a hybrid treatment, drawing on elements of CBT and SST both of which 
have been shown to be beneficial in reducing negative symptoms (Elis et al, 
2013). A prominent issue that emerges in the synthesis of both studies (Eack et 
al, 2013; Granholm et al, 2014) relates to the multiple treatment elements that 
will have complex and interacting effects on negative symptom outcomes.  
Two treatments utilised different theoretical backgrounds to conceptualise 
interventions which differ from the more mainstream techniques described 
above. Loving Kindness Meditation (LKM; Johnson et al, 2009; Johnson et al, 
2011) assumes that patients need to re-learn the ability to feel warmth, 
compassion, and connectedness. LKM draws upon third-wave CBT elements (e.g. 
relaxation and meditation) with an aim to develop these skills thus increasing 
feelings of warmth and compassion for self, and others. This is postulated to then 
impact on a person’s life experiences and their emotional responses. This overall 
process is based on Fredrickson’s (2001) broaden-and-build theory which 
stipulates that developing one’s experience of positive emotions has a beneficial 
impact on psychological resources and overall well-being.  
Röhricht and Priebe (2006) report on a novel intervention for negative 
symptoms focussing on physical movement. Body-orientated Psychotherapy 
(BPT) is based on an assumed link between physical movement and emotional 
experience and thus targets specific negative symptoms (flat affect and motor 
retardation). A more recent pre/post study of BPT (Röhricht et al, 2011) was 
delivered following the approach described by Röhricht and Priebe (2006) – yet 
there are discrepancies in the reported effectiveness of BPT across these two 
trials.  
Commonalities across Studies 
Design 
Four randomised controlled trials (RCT) were included in this review (Granholm 
et al, 2014; Grant et al, 2012; Klingberg et al, 2011; Röhricht & Priebe, 2006). Eack 
et al (2013) utilised an exploratory post hoc analysis of a previous RCT study 
which identified significant intervention effects on negative symptoms. An issue 
is highlighted in the variance of comparator therapy in each of these studies and 
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the intervention dosage between the experimental/control groups within the 
same study may not be matched. 
Röhricht et al (2011) utilised a pilot study to evaluate their intervention in open 
clinical settings and Johnson et al (2011) adopted a similar design for their 
pilot/feasibility study. Three studies (Favrod et al, 2010; Favrod et al, 2015; 
Johns et al, 2002) were also pilots of novel interventions and employed before-
and-after designs. A case study design was used by Johnson et al (2009) to 
illustrate the impact of their intervention in people with different presentations 
of negative symptoms. 
Addressing Secondary Symptoms in Methodology 
Only five papers assessed secondary negative symptoms in their methodology. 
Favrod et al (2010) assessed depression at pre-test only whereas Klingberg et al 
(2011) included depression assessment as a secondary endpoint. Depression 
was also assessed at pre/post in the PEPS pilot and an analysis was completed to 
extricate negative symptoms from depression (Favrod et al, 2015); a similar 
approach was used by Johns et al (2002). The primary outcome measures in the 
BPT trial (Röhricht & Priebe, 2006) are explicitly stated to measure primary 
negative symptoms, with secondary negative symptoms (i.e. extrapyramidal 
symptoms) accounted for with a different measure.  
Sample Characteristics 
Participants in the included studies were all male or female adults (18-65) with 
a mix of diagnoses along the schizophrenia/psychosis spectrum. Sample size 
varied by study and ranged from 3-198. 
Four studies included participants with an explicit diagnosis of schizophrenia 
(Favrod et al, 2010; Klingberg et al, 2011; Röhricht & Priebe, 2006; Röhricht et 
al, 2011). The LKM studies had added diagnosis inclusions of both psychotic 
disorder NOS and schizophreniform disorder. Eack et al (2013) included 
schizophrenia, schizoaffective, and schizophreniform disorder all in their early 
course (Eack et al, 2013). The remaining studies included participants with a 
diagnosis of either schizophrenia or schizoaffective disorder.  
Six studies reported negative symptoms specifically as part of their inclusion 
criteria (Favrod et al, 2015; Grant et al, 2012; Johns et al, 2002; Klingberg et al, 
2011; Röhricht & Priebe, 2006; Röhricht et al, 2011). Johnson et al (2011) 
indicated negative symptoms were measured for participants but this was not 
stated as an explicit inclusion criteria. Exclusion criteria varied by study and 
included factors such as organic disease that may impact on cognitive functioning 
(e.g. Grant et al, 2012) or prior exposure to the intervention being investigated 
(e.g. Granholm et al, 2014). Two studies did not stipulate exclusion criteria 
(Favrod et al 2015; Johnson et al, 2009) and one study did not explicitly state 
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either inclusion or exclusion criteria (Johnson et al, 2011). Only two studies 
provided sample size calculations (Klingberg et al, 2011; Röhricht & Priebe, 
2006). 
The reported mean duration of illness ranged from 3.19 to 21.3 years with four 
studies not stating this information explicitly (Favrod et al, 2010; Klingberg et al, 
2011; Johnson et al 2009; Johnson et al 2011). A number of studies indicated 
participants were on standard medication. Two studies (Eack et al 2013; 
Röhricht & Priebe, 2006) explicitly stated changes in medication were permitted 
during the course of participation.  
Delivery Format 
Eight studies utilised group therapy format (Eack et al, 2013; Favrod et al, 2015; 
Granholm et al, 2014; Johns et al, 2002; Johnson et al, 2009; Johnson et al, 2011; 
Röhricht & Priebe, 2006; Röhricht et al, 2011) with the two CBT trials adopting a 
one-to-one format (Grant et al, 2012; Klingberg et al, 2011).  
Favrod et al (2010) described two of their five participants receiving group 
therapy while the others received individual therapy. There is no rationale 
provided for this but the authors note that an attempt was made to meet 
individual needs of participants.  There was a wide range of professional 
experience in therapists delivering interventions (see Table 3).  
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Table 3: Treatment Resources 
Study Number of Sessions Duration of 
Sessions 
Delivery 
format 
Therapist Characteristics 
Eack et al 
2013 
45 socio-cognitive  
+ 
60 computer based, delivered 
over 24 months. 
 
60-90 mins. 
 
Group. 
 
Nurse specialists (MSc’s). 
Favrod et al 
2010 
Varied, mean hours of therapy 
17.6 hrs 
Unclear. Individual 
/Group. 
 
Not explicitly stated. 
Favrod et al 
2015 
8. 60 mins. Group. Nurses, nursing assistants, & 
social workers trained (1 
day) in the intervention. 
Granholm 
et al 2014 
36 over 9 months, 12 boosters 
monthly. 
120 mins with 
break & a snack. 
Group. 2 MSc or PhD therapists with 
min 2 year CBT experience. 
Grant et al 
2012 
Up to 72 (scheduled weekly 
for 18 months). 
50 mins. Individual. Doctoral level (PhD or MD). 
Johns et al 
2002 
16. 1 to 2.5 hours with 
a break. 
Group. Clinical psychologists (PhD; 2 
per group). 
Johnson et 
al 2009 
6, with one review 6 weeks 
post treatment. 
60 mins. Group. Marriage & family therapist 
(MSc) with 25 years 
meditation experience. 
Johnson et 
al 2011 
6, with one review 6 weeks 
post treatment. 
60 mins. Group. Marriage & family therapist 
(MSc) with 25 years 
meditation experience. 
Klingberg 
et al 2011 
20. Mean 51.8 mins. Individual. 5 clinical psychologists varied 
experience (MSc’s/3 had 
additional 3 year CBT 
training). 
Rohricht & 
Priebe, 
2006. 
20. 
 
60-90 mins. Group. Part-time dance movement 
therapist. 
Röhricht et 
al 2011 
20. 60-90 mins. Group. Dance therapists. 
 
Dose and Duration 
Three studies describe large dosage ranges with 36 to 72 sessions delivered over 
a number of months (see Table 3; Eack et al, 2013; Granholm et al, 2014; Grant 
et al, 2012; Klingberg et al, 2011). Additional therapeutic input is also highlighted 
in the CET study in the form of computer-based sessions (Eack et al, 2013) and 
Granholm et al (2014) indicated extra dosage through individual goal setting 
sessions prior to intervention, counter-balanced across treatment arms.  
Four studies indicate a moderate dosage rate of 16 to 20 sessions (Johns et al, 
2002; Klingberg et al, 2011; Röhricht & Priebe, 2006; Röhricht et al, 2011) with 
the remaining studies detailing low dosage (Favrod et al, 2010; Favrod et al, 
2015; Johnson et al, 2009; Johnson et al, 2011).  
The duration of sessions varied by study but were all within a range of 50-180 
minutes. The longer sessions were accompanied by a break (i.e. Granholm et al, 
2014; Johns et al, 2002).  
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Psychosocial Techniques Utilised 
The descriptions for interventions varies in the amount of detail each paper 
provides. In general, included information tends to be brief and lacks enough 
descriptive data to be able to gain a comprehensive understanding of the 
intervention.  
However, the information that is available does provide a general idea of each 
intervention and the techniques used within. Some explanations provide 
coherent explanations of intervention rationale, techniques, and related 
outcomes (e.g. Favrod et al, 2015).  Other papers provide contradictory evidence 
of the effectiveness of interventions following the same treatment manual, such 
as the different impact of BPT on motor retardation across both studies (Röhricht 
& Priebe, 2006; Röhricht et al, 2011). 
Some interventions report beneficial outcomes on pre-specified targeted 
negative symptoms (e.g. Favrod et al, 2010; Röhricht & Priebe, 2006). However, 
Röhricht and Priebe’s description of the BPT intervention indicates a large 
repertoire of biopsychosocial techniques (e.g. body movement, group exercise, 
reflection) making linkages between a technique and negative symptom domain 
difficult. This is a pattern across all of the included studies.  
Thematic Analysis of Psychosocial Techniques 
Thematic analysis techniques were employed to aggregate and synthesise 
psychosocial techniques common across the included studies. The themes 
represent treatment components that may have beneficial impact on negative 
symptoms. Table 4 indicates the six most common themes. 
  
23 
 
Table 4 – Psychosocial Technique Themes 
Theme Example(s) 
 
Providing education on psychological processes 
involved in negative symptoms and for the theory of 
the given intervention 
 
 
“The group content included: psychoeducation and understanding 
negative symptoms…” (Johns, et al (2002)). 
 
 
 
 
Developing generic problem solving skills that enable 
people to understand and respond to everyday 
challenges. 
 
 
“…The focus was on developing specific, feasible plans to solve real-
world problems, including scheduling pleasant activities, improving 
living situations, handling finances, using public transportation, 
finding a volunteer or paid job, and enrolling in classes…” 
(Granholm et al, 2014). 
 
 
Developing skills to help people effectively 
communicate positive emotions to others through 
verbalisation and/or body language. 
 
“…Increasing behavioural expression of emotion involves using 
facial expressions or gestures to accompany that positive emotion…” 
(Favrod et al., 2015). 
 
 
Developing the ability to set realistic goals and 
supporting people to achieve this. 
 
“…Therapy aimed to stimulate patients’ interest and motivation to 
focus respectively on achievable long-term goals...intermediate-
goals and short-term goals…” (Grant et al, 2012). 
 
Building motivation to practise the skills from therapy 
outside of the therapeutic context. 
 
“…collaboratively devised action plans for practice outside the 
session…” (Grant et al, 2012).  
 
“…A simple homework task is assigned to be done between each 
session…” (Favrod et al (2015). 
 
Developing skills focussed on challenging unhelpful 
beliefs associated with negative symptoms (i.e. 
challenging nihilistic beliefs). 
 
 
“…thought challenging skills were the exclusive focus…. (e.g. to 
address defeatist attitudes and other thoughts that could be 
obstacles to skill learning or goal achievement)…” (Granholm et al, 
2014). 
 
Objective 2 - What specific negative symptoms do these techniques improve and 
how are improvements measured? 
As can be seen from Table 2 above, common targets are symptoms in the 
diminished experiential subdomain, with avolition and anhedonia reported to be 
amenable to psychosocial intervention. There is considerable variability in the 
chosen primary outcomes and standardised measures across the included 
studies. The Scale for the Assessment of Negative Symptoms (SANS; Andreasen, 
1984) is the most common, appearing in six of the study methodologies, with the 
Positive and Negative Syndrome Scale for Schizophrenia (PANSS; Kay, Fiszbein, 
and Opler, 1987) appearing in four.   
The use of specific subscales of various psychometric outcome measurements to 
detect changes in negative symptoms presents a problem when attempting to 
analyse effects across studies. Further issues are indicated when considering 
discrepancies between therapist and participant ratings (e.g. Röhricht et al 
(2011) describe participants providing higher self-ratings in measures of affect) 
and the variance in targeted symptoms across each study.   
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Objective 3 - How acceptable are the interventions and the associated outcomes 
to patients?  
Three papers explicitly address participant satisfaction with intervention as 
primary outcomes in their methodologies, with one utilising a standardised 
measure to assess this (Röhricht & Priebe, 2006) and the others non-
standardised methods (e.g. questionnaires; Johnson et al, 2011; Johns et al, 
2002). All three studies indicate participants reported positive satisfaction with 
interventions. However, in the RCT of BPT this did not differ from the comparator 
group.  
Granholm et al (2014) do not measure satisfaction but focus on treatment fidelity 
and adherence, which can give an indication of satisfaction (i.e. higher adherence 
may indicate greater satisfaction). The LKM case studies (Johnson et al, 2009) 
provide anecdotal evidence of treatment satisfaction. The six remaining papers 
do not assess for participant satisfaction with intervention.  
 
Discussion 
The aim of the review was to analyse effective psychosocial treatments for 
specific negative symptoms. Elis et al (2013) highlighted the need to describe 
effective components of interventions to develop current understanding of 
mechanisms of change, which could lead to more effective treatments (Kaiser et 
al, 2016). A total of 11 studies with treatment approaches from different 
theoretical perspectives and with various methodologies/outcomes were 
included. Narrative synthesis techniques were employed and opportunities to 
move this field of research further were identified.  
Main Findings 
Variability in Methodological and Conceptual Approaches 
Nine of the 11 studies reported clinically significant positive effects on negative 
symptoms.  Similar to the review by Elis et al (2013), the present synthesis 
revealed heterogeneity across various important aspects of study methodologies, 
which complicated cross-study comparison (e.g. variation in measurement of 
negative symptoms). Some studies used pilot before-and-after designs 
employing a very small sample (e.g. Favrod et al, 2010; Johns et al, 2002), whilst 
others had a large sample, and high dosage RCT design (e.g. Granholm et al, 
2014). Certain interventions (Eack et al, 2013; Favrod et al, 2010) required 
substantial cognitive abilities from a population who experience known 
problems in neurocognitive functioning (Foussias et al, 2014).  The RCT’s all used 
a different comparator with various follow-up points and the intervention dosage 
between the experimental and control groups within the same study may not be 
matched (see Eack et al, 2013). A number of samples included mixed diagnoses 
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of schizophrenia and schizoaffective disorder which becomes problematic in 
relation to the debate around negative symptom severity (Foussias et al, 2014). 
For example, negative symptoms in schizophrenia may be more severe than 
schizoaffective disorder which may impact on outcomes.  While early trials of a 
novel treatment (Röhricht & Priebe, 2006; Röhricht et al, 2011) indicated 
positive outcomes for negative symptoms, a more recent multisite RCT indicated 
this effect was not replicated (Priebe et al, 2016).    
Additionally, the process of this review indicated a general problem with the 
current intervention literature in relation to studies not subdividing negative 
symptoms. For example, Staring, Huurne, and van der Gaag’s (2013) pilot of CBT 
for negative symptoms was excluded from this review as it failed to provide 
outcomes related to specific negative symptom subdomains. In addition, a recent 
review (Aleman et al, 2016) also focused on general negative symptom reduction. 
Future research may need to employ validated outcome measurements that are 
specific to negative symptoms (e.g. see Strauss and Gold, 2016) which can then 
be used to reliably identify specific negative symptoms. This would allow for a 
better understanding of the pathway between an intervention component to an 
outcome in a specific negative symptom (e.g. amotivation or apathy). This may 
then indicate what particular mechanism of change is responsible for the 
outcome.  
 
Overall, this highlights the ongoing need to develop a better understanding of 
specific negative symptoms and their treatment. The recent changes in our 
understanding of symptoms (e.g. expressive versus experiential deficits) has led 
to a number of different treatment approaches all targeting various aspects of 
negative symptoms. Research may need to begin separating these symptoms to 
aid the identification of mechanisms of change (e.g. Kaiser et al, 2016), ultimately 
leading to more effective and efficient interventions.  
Intervention Description 
CONSORT guidelines (Schulz, Altman, and Moher, 2010) indicate trials should 
provide sufficient detail for study replication. Broadly speaking, authors of the 
included studies are constricted to brief descriptions of interventions. While 
protocols may exist for some (e.g. Röhricht & Priebe, 2006) they are not always 
available in the published manuscripts and adaptations may have been made to 
existing protocols without explicit information as to the nature of these 
adaptions (i.e. Grant et al, 2012).  
This indicates a problem with the ways in which interventions are reported in 
the literature in general. The lack of full intervention description leaves readers 
with a poor understanding of the psychosocial components involved. It would be 
prudent for intervention studies to include a detailed step-by-step description of 
the intervention and/or full protocol. This would help to focus treatment on 
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clearly defined negative symptom targets and elucidate links between reported 
outcomes and mechanisms of change. This issue also indicates a need for a 
taxonomy of behaviour change techniques that can be mapped onto 
interventions (see Michie, van Stralen, and West, 2011).  
Strengths and Limitations  
This review is the first of its kind to attempt to disentangle and analyse effective 
psychosocial intervention components that explicitly target specific negative 
symptoms. The synthesis provides salient information that may be beneficial in 
developing further research into psychosocial interventions for negative 
symptoms.  
Due to the heterogeneity of studies included in this review a meta-analysis could 
not be completed. This confounded the possibility of comparing any effect sizes 
of reported outcomes in trials. Despite this, the qualitative synthesis allowed for 
a variety of studies to be reviewed. The authors of this review have made every 
attempt to be transparent through the description of methods and synthesis of 
results.  
Thematic analysis identified treatment components common across included 
studies.  Negative symptoms in the diminished experiential subdomain were 
identified as amenable to psychosocial intervention. Taken together, this 
information might be used as a starting point for future research into treatments 
for negative symptoms.  
 
Overall, the review highlights numerous approaches to psychosocial treatment 
of negative symptoms. Perhaps as the scientific evidence matures more robust 
techniques (i.e. meta-analysis) can be applied in future reviews. Currently there 
are multiple intervention techniques being utilised, often packaged in 
idiosyncratic ways, and assessed with a variety of outcome measures. This 
indicates a need for developing new research with specific negative symptoms as 
a primary outcome measure.  
Recommendations for Future Research 
Future studies could use Michie et al’s (2011) behaviour change taxonomy as a 
focus for conceptualising interventions for negative symptoms. Research focused 
on intervention development could utilise the current findings to promote an 
approach to targeting single negative symptoms. A transdiagnostic approach 
may help to eliminate the confounding factors of symptom severity across 
diagnoses.  
Many participants were on long-term medication which adds the confounding 
variable of negative symptoms related to extrapyramidal side-effects (e.g. see 
Foussias et al, 2014).  There is also a lack of focus on disentangling primary and 
27 
 
negative symptoms across some methodologies. More robust study 
methodologies may be able to address these issues, perhaps through the process 
of randomisation, which a number of included studies did not utilise.  
The majority of studies did not assess the acceptability of interventions for 
participants; future studies will need to address this. Some studies utilise 
substantial resources (e.g. 72 sessions of CBT). This is important when 
considering the long-term goal of application to clinical practice. MRC guidance 
(Craig et al, 2008) indicates products need to match the expectations of their 
consumers – understanding acceptability is a key factor in this.  
 
Conclusions 
Recent studies indicate discrepancies in patient versus therapist views on 
treatment goals for schizophrenia (Moritz et al, 2016; Sterk et al, 2013). In 
general this emergent literature indicates that patients and their families/carers 
desire help with negative symptoms and indicate specific subdomains that could 
be targeted (e.g. avolition). The present review indicates psychosocial treatments 
are emerging yet this field of research needs further development. The analysis 
indicated that avolition may be responsive to psychosocial intervention and the 
themes identified provide examples of techniques that may impact on this 
subdomain. However, there remains a need to explore what the key negative 
symptom subdomain targets are for psychosocial intervention based on the 
opinions of those with the most experience – people who experience negative 
symptoms, their carers, and professional carers.    
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Plain English Summary 
Introduction:  
People with schizophrenia experience symptoms classified as positive (i.e. a 
change in behaviour of thinking) and negative (i.e. a change in emotions). 
Negative symptoms in schizophrenia are characterised by a lack of motivation, 
enjoyment and engagement in everyday activities. Up to 30% of individuals 
with chronic schizophrenia have negative symptoms.  
However, there remains a gap in knowledge about effective psychosocial (i.e. 
non-medicated) treatments due to the variability in current approaches (Elis, 
Caponigro and Kring, 2013). There have been recent attempts by clinicians and 
researchers to clarify what specific negative symptoms should be targeted and 
how therapeutic change should be measured. Major stakeholders’ views (e.g. 
service users and carers) would provide further knowledge on the experience 
of negative symptoms and in the development of effective treatments (Schooler 
et al, 2015). Additionally, this information may provide valuable insight into 
ways in which new interventions can be incorporated into everyday clinical 
practice.  
Methods: 
A review of the relevant literature associated with psychosocial treatment of 
negative symptoms was conducted. Data was analysed and important treatment 
factors, such as treatment preference and improvements in specific symptoms, 
were identified. This information was used to develop an interview script with 
questions based on these factors and service users, carers, and healthcare 
professionals were invited to participate in interviews. Interviews were 
recorded and transcribed. Data was then analysed using thematic analysis (a 
technique used to find important themes in written data). The study was 
conducted at two NHS mental health sites (one inpatient and one community) 
to try and capture a broad view of different perspectives. The study was given 
ethical approval and individuals provided written consent to participate.  
Results: 
A common theme across all groups is the need for treatments to be tailored to 
individual preferences. Other themes indicate the need for a well-informed, 
graded approach to therapy which is supported by organisational resources 
with staff training needs addressed. There was disagreement in treatment 
preferences across groups in relation to treatment of specific negative 
symptoms. 
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Discussion 
The need for treatments to be tailored to individuals is consistent with the 
current recovery movement which places importance on outcome factors such 
as empowerment and meaning in life. The findings indicate further work is 
needed to understand treatment preferences across different groups which has 
been identified as a need for schizophrenia treatment in general. There are 
barriers to interventions being successfully implemented and findings suggest 
solutions to these problems, for example through staff training.  
Conclusions 
An individualised approach to psychosocial treatment of negative symptoms is 
needed. There is disagreement in treatment preferences for negative symptoms 
across major stakeholders.  Further research focusing on patient treatment 
preferences is needed.  
References: 
Elis, O., Caponigro, J. M. & Kring, A. M. (2013). Psychosocial treatments for 
negative symptoms in schizophrenia: Current practices and future directions. 
Clinical Psychology Review, 33, 914-928. 
Schooler, N.R., et al., (2015). Defining therapeutic benefit for people with 
schizophrenia: Focus on negative symptoms. Schizophrenia Research. Available 
from http://dx.doi.org/10.1016/j.schres.2014.12.001 [Retrieved 06.01.2015] 
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Abstract 
Objectives. Recent literature indicates variance in psychosocial treatment 
preferences for negative symptoms of schizophrenia. Attempts at defining 
therapeutic aims and outcomes for negative symptoms to date have not included 
major stakeholder groups.  The aim of the present study was to address this gap 
through qualitative methods.  
Design. Thematic Analysis was applied to qualitative semi-structured interview 
data to gather the opinions of people who experience negative symptoms, carers, 
and healthcare professionals. Participants were recruited from two mental 
health sites (inpatient/community) to increase generalisability of results. Ten 
people participated in the research. 
Methods. Semi-structured interview scripts were designed utilising evidence 
from the review in Chapter 1 of effective psychosocial intervention components 
for specific negative symptoms. Interviews were audio recorded and transcribed 
verbatim. Thematic analysis was employed to analyse data.  
Results. A common theme across groups was the need for a personalised 
approach to intervention for negative symptoms. Other themes indicated 
different opinions in relation to treatment targets and the need for a sensitive 
and graded approach to all aspects of therapy. This approach needs to be 
supported across systemic levels of organisation with specific training needs for 
staff addressed. 
Conclusions. There is disparity in treatment preferences for negative symptoms 
across major stakeholders. The findings suggest an individualised approach to 
intervention of negative symptoms that is consistent with recovery. 
Implementation barriers and facilitators were identified and discussed. There 
remains a need to develop a better understanding of treatment preferences for 
patients.  
 
Practitioner points 
 Interventions need to be developed in line with major stakeholder 
preferences and consistent with recovery. 
 Healthcare professionals may require specific training for working with 
this population. 
 Organisations need to commit to supporting intervention development 
and implementation in order to produce positive gains for this population 
that can be maintained over time.  
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Introduction  
Negative Symptoms 
Recent years have seen a focused approach to the scientific understanding and 
clinical treatment of negative symptoms in schizophrenia. This is an important 
area for research when considering these symptoms are core features of the 
illness (Bleuler, 1950) and issues such as debate related to the content of 
professional guidelines for schizophrenia treatments (e.g. NICE versus SIGN; see 
Kendall et al, 2016). It is reported that 20-40% of individuals with long-term 
illness experience negative symptoms (an der Heiden, Leber, & Hafner, 2016). 
Negative symptoms of schizophrenia are part of a discrete domain separate from 
other common features of the illness (Foussias and Remington, 2010). Difficulties 
exist in differentiating primary negative symptoms (i.e. illness related) from 
secondary symptoms (related to various factors, such as the experience of 
psychosis itself). Complications like these can have an impact on factors such as 
obtaining accurate prevalence rates or on methodologies employed in treatment 
trials (see Mucci, Merlotti, Ucok, Aleman, & Galderisi, 2016).  
Furthermore, Galderisi, Farden, and Kaiser (2016) draw attention to the variance 
amongst researchers in relation to the methods of assessment of negative 
symptoms and models for understanding their underlying mechanisms. The 
severity of these symptoms can impact on therapeutic outcomes for patients 
experiencing schizophrenia (Foussias, Agid, Fervaha, & Remington, 2014), yet 
there is a current need to develop comprehensive psychosocial interventions in 
tackling these symptoms (Aleman et al, 2016).  
It may be that disparity amongst clinicians and researchers in relation to the 
notion of recovery (e.g. Slade, 2012) adds to the challenge in developing effective 
treatments. Recent years have seen the evolution of the recovery movement in 
mental illness. The CHIME conceptual framework (Leamy, Bird, Le Boutillier, 
Williams, and Slade, 2011) highlights a greater emphasis on idiosyncratic 
outcomes (i.e. personal meaning) as opposed to typical nomothetic outcomes 
reported in studies focussing on ‘clinical recovery’. For instance, a recent review 
indicates the literature on recovery in negative symptoms tends to focus on 
symptomatic reduction and/or functional outcomes (see Valencia, Caraveo, 
Colin, Verduzo, & Coronoa, 2014). Additionally, there is noted variance in patient 
versus clinician preferences for treatment outcomes in schizophrenia (Moritz, 
Berna, Jaeger, Westermann, & Nagel, 2016; Sterk, Winter, Muis, & de Haan, 2013). 
This disparity indicates a need for research to explore treatment targets and 
outcomes most relevant to key stakeholders in relation to negative symptoms. 
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 A recent clinician-researcher panel (Schooler et al, 2015) partially addressed 
this need by providing a consensus statement detailing a set of criteria upon 
which therapeutic impact on negative symptoms can be measured. There is a 
specific focus on symptom remission (or decrease in intensity) and functional 
outcomes.  However, this does not seem to fit the framework and ideas fuelling 
the current recovery movement.  Additionally, as the authors note, key 
stakeholders (e.g. patients, professional/family carers, and policy makers) were 
not included in the panel. This needs addressed to gain a better understanding of 
negative symptoms and their treatment.  Furthermore, this lack of a universally 
agreed definition draws attention to the gap in current knowledge on negative 
symptom treatment.  
Psychosocial Intervention 
Intervention is complicated when considering people with schizophrenia are 
thought to experience poor insight into their illness (Lysaker et al, 2011a) and 
may struggle with metacognition in general (Lysaker et al, 2011b). Specifically, 
they may struggle to understand themselves and the people around them, 
making psychotherapy a difficult process to engage in. People with negative 
symptoms can also experience comorbidity of other psychiatric illnesses (e.g. 
depression; see Buckley, Miller, Lehrer & Castle, 2009).  
A recent comprehensive review of psychosocial treatments for negative 
symptoms indicates positive outcomes (Elis, Caponigro, & Kring, 2013). Elis et al 
focus on three types of intervention – cognitive behavioural therapy (CBT), social 
skills training (SST) and combined treatment interventions. The review specifies 
that psychosocial treatments have the potential to alleviate negative symptoms. 
Yet, outcomes are reported in relation to impact on negative symptoms in general 
(i.e. reduction of total scores on measures) and the variance in outcomes (e.g. 
maintenance factors at follow up) makes cross treatment comparisons difficult. 
Furthermore, Aleman et al’s (2016) more recent review also highlights the lack 
of interventions focussed on treating specific negative symptoms. This is a key 
area for research in order to develop a treatment acceptable to stakeholders that 
is targeted at specific domains of negative symptoms and can be implemented in 
clinical practice. 
Implementation 
Wykes (2016) indicates an urgent need for research related to patient preference 
and informed treatment in schizophrenia in order for this to be disseminated for 
implementation in clinical practice. The Medical Research Council’s (MRC) 
framework for complex interventions (Craig, Dieppe, Macintyre, Michie, 
Nazareth, & Petticrew, 2008) details a phased approach to the development and 
implementation of interventions. A key message from the MRC relates to the 
importance of investment at the development stage of research, prior to large 
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scale evaluations.  This approach may tackle noted problems related to 
empirically formulated interventions not achieving successful implementation in 
everyday clinical settings (Durlak & Dupree, 2008). To tackle implementation 
issues there is a need to understand stakeholders’ perspectives in relation to 
treatment preferences. Obtaining the opinions of these groups will provide 
evidence that will improve treatment targeting for negative symptoms and also 
provide knowledge related to implementation issues.   The development of future 
interventions for negative symptoms will benefit from this knowledge.   
Exploration of Stakeholder Opinions 
Qualitative research in the field of schizophrenia has added to scientific 
understanding of the experiential nature of the illness (McCarthy-Jones, Marriott, 
Knowles, Rowse, & Thompson, 2013). Furthermore, qualitative methodology can 
provide a robust framework for exploration and discovery when consideration is 
given to sampling procedures (e.g. utilising specific inclusion/exclusion criteria 
with generalisability in mind; Lewis & Ritchie, 2003). 
Waller et al (2013) utilised thematic analysis to explore key stakeholder views 
on their experiences of participating in a pilot of a novel low intensity CBT 
intervention for psychosis. Waller et al conducted semi-structured interviews 
with both staff and service users to investigate the positive/negative factors 
associated with the intervention. An additional factor they explored with the staff 
group related to the feasibility of long-term implementation of the intervention.  
This process provided a wealth of data which would not be captured using 
quantitative methodologies. Therefore, explorative methodologies may be an 
efficient approach to engage with stakeholders in relation to negative symptoms.  
The present study will utilise qualitative methods to provide further clarity in 
relation to the consensus statement provided by Schooler et al (2015). The study 
aims to address the gap in current knowledge by gaining an understanding of 
negative symptoms and their treatment from the experience of major 
stakeholders. 
Specifically, the study will draw upon the methodology used by Waller et al 
(2013) with a focus on consulting patients and family/professional carers to 
explore their views on negative symptoms and their treatment. The exploration 
will be guided by the findings from the systematic review in Chapter 1. 
The study aims to explore key areas, including: treatment need for negative 
symptoms; the specific negative symptoms that could be targeted; the preferred 
method of intervention; the philosophy underpinning recovery; and challenges 
related to implementation.  
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Methods 
Design  
Thematic Analysis (Braun & Clarke, 2006) was applied to qualitative semi-
structured interviews consisting of prompt questions. Interview scripts were 
derived from the systematic review of the literature and two versions were 
produced. One script targeted patients (see Appendix 2.1) and the other 
carers/healthcare professionals (see Appendix 2.2). The scripts were used 
primarily as a guide for the researcher during interviews as it was recognised the 
language used in scripts would need to be adjusted to individual needs. As part 
of this research participants were invited to be consultants at future information 
events related to the study topic (see Appendix 2.3). 
Participants 
The qualitative design of the study allowed for a small sample to be recruited 
which enabled a deeper exploration of individual experience during interview. 
Participants were recruited between April 2016 and June 2016 from two NHS 
sites in Scotland (inpatient/community).  An attempt was made to recruit even 
numbers from each group through opportunity sampling across both the 
community and inpatient settings in order to provide a representative sample. 
Three groups were recruited – patients, carers, and healthcare professionals – 
using information sheets tailored by group and location (for examples of these 
see Appendices 2.4, 2.5, & 2.6 respectively). Mental health teams at both sites 
were approached to participate in the study and to aid with recruitment. Carers 
were identified by the teams and invited to participate by letter (see Appendix 
2.7). Recruitment of inpatients proved to be difficult with a number of people 
stating an interest but refusing to participate on the day. The principal researcher 
tried to visit the inpatient site at various times during the day to be available to 
speak to people. However, despite this, recruitment of patients at the inpatient 
site was unsuccessful.    
Separate inclusion/exclusion criteria were applied to ensure homogeneity 
within groups – a salient factor in exploration of subjective experiences. Inclusion 
criteria for patients were: a) adults with a diagnosis of schizophrenia or related 
psychoses with experience of negative symptoms, and b) aged 18-65 to fit with 
referral criteria for Adult Mental Health services.   Exclusion criteria: present 
experience of substance abuse, low cognitive functioning, or capacity and consent 
issues. Teams identified carers with extensive of experience in caring for 
someone with negative symptoms. Inclusion criteria for healthcare professionals 
was experience of working in face-to-face therapeutic setting with people who 
experience negative symptom. Exclusion criteria were: a) no experience of 
working with people who experience negative symptoms, b) those who do not 
engage in psychosocial therapeutic work with people who experience negative 
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symptoms. A total of 10 participants consented to the research (two patients, 
four carers, and four healthcare professionals). See Tables 1 and 2 for participant 
demographics. 
Table 1 – Patient Demographics 
 
ID 
 
Gender 
 
Age 
 
Diagnosis 
 
Duration of 
Illness (years) 
P1 M 44 Treatment Resistant 
Schizophrenia 
>25 
P2 M 47 Schizophrenia >20 
* > - over, M – male. 
Table 2 – Carer and Healthcare Professional Demographics 
 
ID 
 
Gender 
 
Age 
 
Role 
 
Years of 
experience 
C1 M 81 C >25 
C2 F 70 C >25 
C3 F 60 C >30 
C4 F 72 C >25 
HP1 F 49 CPN 31 
HP2 F 59 CPN 18 
HP3 F 35 SOT 6 
HP4 M 49 CN 20 
* > - over, M – Male, F – Female, – carer, CPN – Community Psychiatric Nurse, SOT – Specialist Occupational Therapist, 
CN – Charge Nurse 
Procedure 
Participants were invited to take part in interviews lasting approximately 30 
minutes with the principal researcher at each NHS site. Prior to interview 
participants provided written consent. Interviews were audio recorded and 
transcribed verbatim. Personal identifiers were removed to ensure anonymity. A 
debrief post-interview allowed for general discussion and the chance for 
participants to ask questions regarding the research.  
Data Analysis 
 
Analysis of data was conducted following thematic analysis guidance (Braun & 
Clarke, 2006). Thematic analysis was chosen as it is free from being rooted in any 
pre-existing theoretical frameworks and is flexible in its application across 
various epistemologies (Braun & Clarke, 2012). For instance, thematic analysis 
can be applied across a variety of theoretical frameworks and within these allows 
researchers to provide a transparent position of theoretical stance in relation to 
the analysis of data (Braun and Clarke, 2012). The analysis process included the 
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production of an initial coding framework developed through the independent 
coding of a full interview transcript by two authors (PS and HM). The progression 
of analysis included using the coding framework while reading and re-reading all 
transcripts. This process led to a re-iteration of the coding framework and 
manuscripts were re-analysed. Some themes were anticipated through the semi-
structured interview questions, yet other unexpected themes and associated sub-
themes emerged through this process.  
 
Reflexivity 
The principal researcher adopted an inductive, semantic and realistic approach 
to thematic analysis in line with the research aims of obtaining the subjective 
perspectives of participants. This approach allowed for exploration of individual 
experience and the meaning people attach to these. The principal researcher’s 
competency for the process of interpretation, and understanding, of explicit 
meanings was deemed adequate through his training in clinical psychology and 
previous research experience utilising thematic analysis. Furthermore, the 
principal researcher has direct clinical experience in working with the present 
population. Investigator triangulation was completed by the principal researcher 
and one author (HM) in recognition of potential bias in interpretation of the data.  
Ethical Issues 
An application was submitted to the West of Scotland Research Ethics Service 
and approval was gained (see Appendix 2.8). Further approval was gained from 
each NHS Research and Development departments for the local sites 
participating (see Appendix 2.9 & 2.10). The principles of the Declaration of 
Helsinki (World Medical Association, 1964) were followed throughout this 
research.  
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Results 
Tables 3 and 4 highlight themes and sub-themes identified through the analysis 
process.  These are described below with quotes highlighted to demonstrate 
salient points.  
Table 3 – Patient Themes and Sub-themes 
 
Group Themes Sub-themes 
 
 
Patients 
 
Pre-intervention Considerations 
                Overcoming Inertia 
 
Medical Model Focus 
 
Individual Needs Approach 
                Empowerment of Individuals 
 
Personalised Treatment  
 
Table 4 – Carer and Healthcare Professional Themes and Sub-themes 
Group Themes Sub-themes 
 
 
 
 
 
 
 
 
 
Carers and 
Healthcare 
Professionals 
 
Individual Needs Approach 
Choice and Values 
 
Attunement and 
Personalised Treatment 
 
 
Informed Intervention 
Treatment Targets 
 
Graded and Flexible 
Approach 
 
Well-timed/Safe 
Intervention 
 
 
Whole Systems Approach 
Education and Awareness  
 
Staff Training  
 
Barriers to Treatment 
 
Complexity 
Interplay of Positive and 
Negative Symptoms 
 
Sensitivity to Psychological 
Processes 
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Patient Interviews 
Pre-intervention Considerations 
Overcoming Inertia. Both participants referred to amotivation in relation to 
engagement in a psychosocial therapy: 
“…I couldn’t be bothered, d’you know what I mean mate, I see X [CPN] at home know 
what I mean?” (P1, page (pp.) 6, line (l.) 192).  
“…I don’t want to talk to people…and they think it, they think that it’s them, that 
I’m not talking to them because maybe they think that I’ve maybe fell out with them 
or something like that but ehm, and usually it’s not it’s me, just can’t be bothered 
doin anything”. (P2, pp. 1, l. 10-16).  
Medical Model Focus. Both participants commented on medication being helpful 
and one participant repeatedly referred back to medication as being a solution to 
problems, indicating perhaps a lack of understanding about psychosocial 
intervention: 
“…Well if it wasn’t for my olanzapine I don’t know where I would be the now, y’know 
that helps a great deal. The medication.” (P2, pp. 10, l. 324-325).  
“… [Response to communication skills question] Oh, well, exact same, take your 
tablets, to help people, take your tablets and that, to help people.” (P1, pp. 3, l. 86). 
“… [Response to goal setting question] Just eh, just, just take your tablets and that 
know what I mean, I don’t know much about that” (P1, pp. 4, l. 104). 
 
Individual Needs Approach 
Empowerment of Individuals. Both participants noted that learning skills would 
be beneficial for individuals who experience negative symptoms in developing a 
sense of autonomy and independence: 
“…Oh just to, to help them and that, to help themselves and that…know what I mean 
to help yourself.” (P1, pp. 5, l. 135). 
“…It makes people independent for themselves.” (P2.pp.3,l.76). 
 
Personalised Treatment. It was apparent from comments across both interviews 
that each individual had their own different preference for the type of therapy 
they would consider participating in. Questions regarding group therapy 
highlight this point: 
“… [Group therapy] had it before…[not helpful]…it’s just, just, it’s the way I am 
d’you know what I mean, it’s the way I am...[felt] uncomfortable…” (P1, pp. 6, l. 165-
173).  
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“…Cause it’s good to all get together… meet other people that’s got the same 
problems.” (P2, pp. 2, l. 45-47).   
 
 
Carer and Healthcare Professional Interviews 
The process of analysis led to a number of core themes being identified across 
both carer and healthcare professional interviews. There were commonalities 
across both groups which led to further analysis and the identification of a final 
set of four main themes with related specific sub-themes.  
Individual Needs Approach  
Choice and Values. The majority of carers commented on the need for careful 
consideration of individual choice within an intervention framework. Two carers 
commented on a collaborative approach to decision making with regards to 
participation in weekly sessions and in reviewing progress: 
“… [if] they were showing anything [progress] then you could say 'how would you 
like to come two days a week?' or something like that…” (C1, pp. 9, l. 314-316). 
 
“…just really say this might be ongoing as long as everybody wants to do this, how'd 
you feel about it? Do we want to have this group every week? Talk about that, what 
you’re getting through it?” (C3, pp. 8, l. 293-295). 
One carer discussed her son’s participation in an art therapy class and reflected 
on the need for interventions to tap into individual interests and values, an aspect 
which may be missing from current treatments: 
“…I suddenly realised that one of the keys for [person with schizophrenia; PwS] 
has been the huge danger that there is of ignoring the sort of slight more emotional 
spiritual creative person in all of that, that's unhelpful not to tap into one of the 
most productive channels he's got for rebuilding his inner self…” (C3, pp. 8, l. 292-
295).  
The notion of values was echoed across healthcare professional interviews with 
a focus on engagement or ‘buy in’ to an intervention: 
“…it’s almost like getting them to want to do it or they, they value it…” (HP3, pp. 3, 
l. 83-84). 
“…the cost/benefit analysis its needs to be much more worthwhile for somebody to 
actually invest in it…” (HP4, pp. 2, l. 44-45).  
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Attunement and Personalised Treatment. Carers indicated the need for 
professionals to be attuned to the individual they are working with. This related 
to various factors, such as noticing an individual’s mood fluctuations or in 
learning how to read non-verbal language over time: 
“…d'you know ways round about it, you know how to eh, bring them on, you know 
how eh, their bad moods you know their bad days you know their characteristics…” 
(C2, pp. 9, l. 324-325). 
“…but I learnt that very quickly how to deal with [PwS] through his body language 
rather, because sometimes [PwS] would not speak for days because the negatives 
were showing their ugly head…” (C3, pp. 3, l. 113-116).  
The need to be attuned to individuals was reflected in various healthcare 
professional comments related to personalised treatment. For example, two 
professionals commented on the need to be attuned to individuals in relation to 
psychoeducation and to intervention delivery format: 
“…I think it [approach to education] might be something individual, it would need 
to be something simple…” (HP2, pp. 3, l. 29-30). 
“…[group delivery format] there are people that might not,  again it might just suit 
to work on a one-to-one basis… there could be something, something specific 
somebody really doesn’t want to discuss and the group thing they might find quite 
embarrassing not got the confidence to discuss…” (HP4, pp. 7, l. 276-279). 
 
Informed Intervention  
Treatment Targets. There was variation in agreement between carers and health 
professionals in relation to treatment targets. Learning how to communicate 
positive emotions was regarded by all professionals to be an important area of 
intervention, with possible benefits for both the individual and for the 
professional, specifically in relation to obtaining patient feedback: 
“…Yep, absolutely, yep, because I think that's something as well that you feel then 
that you're doing something right, the treatment that they are receiving is 
obviously helping, y'know, so they're feeding back to you…” (C1, pp. 4, l. 126-128).  
However, this was not fully representative of carer views with two specifically 
stating individuals retain this particular ability, for example: 
“…I mean let’s say she went to the seaside and enjoyed herself I think she could, I 
mean she could, I think she could express herself there, y’know, I had a good day at 
the beach', y’know.” (C1, pp. 5, l. 181-182). 
“…Oh sometimes he'll wake up in the morning and he'll say to me, mum d'you know 
I’ve got a great day the day…” (C2, pp.3, l. 116-117).  
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Three carers commented that changing beliefs associated with negative 
symptoms would be a difficult process that may take significant effort over a long 
period of time and could also require opportunistic timing for intervention: 
“…it would be really, d’you know, it would be really, really hard… it's very, very hard 
to change their thoughts. See the thought process it's very, I've lived with it all those 
years, it's very very hard to change a thought, you've got to really work at it…” (C2, 
pp. 6, L. 214-217).  
“…just sometimes he's in states where it's very difficult to approach that with him. 
You need to look for windows of opportunity…” (C4, pp. 10, l. 384-386).  
Professional perspectives differed from carers with positive comments on 
challenging thoughts related to negative symptoms and ideas for other areas to 
target: 
“…if you're teaching them to kinda like, almost like CBT approach re-think what 
they’re thinking then brilliant...” (HP3, pp. 5, l. 170-171). 
“…y'know kind of exploring the more, the, the mood type of things and ehm self-
beliefs and self-esteem, self-worth...” (HP2, pp. 6, l. 216-218).   
 
Graded and Flexible Approach. The majority of both groups indicated the need for 
a graded and flexible approach across all aspects of treatment. For example, it 
was important to both groups that goals were: set in line with the individual; 
sensitive to the impact of negative symptoms; realistic and safe: 
“…I think even if you can get them be able to think about what their goals are when 
they’ve got negative symptoms is quite a massive achievement…” (HP3, pp. 4, l. 123-
124).  
“…providing that you keep it [goal setting] reasonable…most setting a target is a 
wee bit out, out with, y’know tryin to, be clever, y’know, and sometimes it upsets the 
whole apple cart.” (C1, pp. 6, l. 203-207). 
Other ideas of grading covered aspects including engagement and skills 
development, safe approaches to thought challenging, and interventions 
characteristics (e.g. format): 
“…generally just try and build that rapport then try and get them do something that 
they enjoy and just build it up and up…” (HP3, pp. 4, l. 134-135). 
“…it's a risk to take and it could either push it to, to the limit, or you could take a 
step back and continue to observe, and the belief could continue and where do you, 
where do you intervene?” (C3, pp. 6, l. 220-222).  
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“…I think combination’s [individual and group therapy] probably the best 
approach, ehm, think yeah, I think one-to-one’s probably the key to starting off…” 
(HP3, pp. 6, l. 220-222).  
While grading of interventions was important it was also clear from both groups 
that a flexible approach must be adopted to meet individual needs: 
“…[engaging in one-to-one therapy] that again’s down to observation, how that 
person is on that particular day…this will work today or no it won’t work today, and 
say oh we'll try it again tomorrow or we'll try it next week when you're feeling a 
wee bit better…” (C3, pp. 7, l. 262-267).  
 
Well-Timed/Safe Intervention. Two carers stressed the importance of well-timed 
intervention in relation to stage of illness with one commenting specifically on 
the present model of crisis intervention and the subsequent lost opportunities 
for people to engage in therapy: 
“…[discussing skills development through intervention]… I think initially of 
course the patient is perhaps in a chronic state that’s not ehm, that might not be 
necessary at that particular point in time….the timing of it is crucial…timing is, is, 
if I was to say, perhaps of the essence in recovery.” (C3, pp. 2, l. 48-58).  
“…[open discussion] ...he gets all the treatment and all the interaction with 
professionals and experts when he is ill rather than well…but even with very ill 
people like [PwS]  there are periods of, eh plateaus, eh, or remission…where there's 
a much greater policy-, possibilities, you know, for logical communication and 
insight for reflection from the patient…yet for some reason contact is almost 
entirely limited to illness and rather than what insight they can get and what 
communication the patient can give them about  how these things affect them and 
what would help them and, to me, that loss is huge…” (C4, pp. 16, 611-620). 
 
The majority of both carers and professionals stressed the need for intervention 
to feel safe for individuals. This related to making change in general, familiarity, 
and the therapeutic environment: 
“…to do something, to make a change or try to work with something to address 
certain issues they’ve got, they’ve got to feel safe...” (HP4, pp. 5, 166-168).  
“… [discussing one-to-one therapy] You'd need somebody familiar with them, see 
likes of X [nurse] somebody from their, they like familiarity…” (C2, pp. 6, l. 234-
235). 
“… [setting] well it has to be relaxed...has to be relaxed, has to be familiar and it has 
to be welcoming, not formal, friendly.” (HP1, pp. 9, 293-294).      
48 
 
 
 
Whole Systems Approach 
Education and Awareness. Two healthcare professionals indicated the need to 
educate individuals about their illness and how a treatment works, with one 
stipulating a need to provide specific information on both positive and negative 
symptoms: 
“…I think encompass the fact that, you know, you can have symptoms like 
hallucinations delusions but what can happen due to this, as well, is the fact that 
you can become a bit depressed, you can become a bit lethargic , lacking motivation, 
volition, you know all these kinda things…” (HCP1, pp. 1, l. 7-9). 
Three carers described a need for education and awareness raising across 
multiple systemic levels. For example, a need was identified for carers/families 
to be well-informed of the illness/treatment and one carer commented on 
personal fears related to the stigma that still surrounds schizophrenia: 
“… [informed of treatment] that would be helpful. I think it would be, yeah a brief 
description or some, some literature that maybe handed out too… to parents or 
carers with regards to ehm the topic he's sitting down and discussing with X 
[therapist]…carers can be left in the dark…” (C3, pp. 1, l. 34-36).  
“… [discussing the impact of providing care] It's worth the hard work, it's really 
worth it because people don’t, either put labels on people, schizophrenic, 'oh god'. 
See although my family know there’s something obviously wrong with [PwS] …how 
does [PwS] not go out on his own or how, y'know, but I couldn’t say he's 
schizophrenic…” (C2, pp. 6, l. 221-225).  
Systemic education was also a need reflected by three professionals focused at 
the levels of individuals, health professionals, and the organisation in general: 
“…[individually tailored psychoeducation] I think it’s having a variety of ways 
cause individuals will suit different ways…I think it really depends on you-, your 
target group, or your individual …”  (HP3, pp. 2, l. 14).  
“…if staff can have a, a kind consistent approach and more empathy…and 
understanding that even might be just more beneficial…” (HP3, pp. 10, l. 337-338).  
“…there’s extreme lack of knowledge about negative symptoms and there's an 
extremely unhelpful [organisational] culture surrounding people’s ability, or 
perceived ability, to help people with negative symptoms,  there's a very negative 
and pessimistic attitude towards helping people with negative symptoms…these 
attitudes pervades, ‘there's not a lot we can do about negative symptoms’, ehm, 
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‘medication doesn’t work for them there’s not much we can do’ ehm, and there’s still 
a culture that I perceive it’s not disappeared…” (HP4, pp. 1, l. 8-25). 
 
Staff Training.  Three healthcare professionals commented on the need for well-
trained staff for working with negative symptoms. Two professionals identified 
specific training needs - to overcome gaps in skills and re-build confidence in 
therapeutic abilities: 
“…I've not really, been able to teach somebody how to, with negative symptoms, 
how to be able to, you know, communicate… I wouldn't say we've been taught the 
skills for that I don’t think…” (HP2, pp. 4, l. 130-135). 
“…people [professionals] don’t feel particularly empowered or skilled, ehm in 
addressing these issues, so for me it’s a fundamental ehm and essential part of 
informing treatment, interventions for patients and training for staff…to make 
them much more skilled and much more confident in going about it, and not to be 
frightened, or feel helpless when working with people with kinda severe negative 
symptoms…” (HP4, pp. 4, 11-17).  
 
Barriers to Treatment. Various barriers were highlighted in the healthcare 
professional group. Engagement was a concern for all professionals: 
“…Eh, they tend to non-engage [in group therapy] ….probably mostly non-
engagement I would say would be the main thing for when…we did group 
therapy…” (HP2, pp. 8, l. 255-257).  
“…somebody's got negative symptoms they're much more difficult to engage in 
those kinds of approaches…” (HP3, pp. 1, 13-15).  
Organisational resources were identified by three professionals as having 
implications for implementing treatments for negative symptoms, with one 
stressing the need for extra support services: 
“…you’ve got resource, trying to find a suitable locations, staff giving up staff time 
for the training and delivery, ehm the commitment yeah, so organisations always 
an issue.” (HP3, pp. 9, l. 324-325).  
“…resources, eh, are really important, having the correct amount of resources the 
correct amount of skill mix to deliver, eh, is vitally important there’s no point in 
starting something I don’t think unless you’ve got that eh support from 
management and recognising it needs to be ring-fenced and fully resourced, 
whether that be staffing or financed ehm, they need to buy into it as an idea you 
can’t go off half cold doing this stuff, there needs to be a commitment that it’s 
something good to do…” (HP4, pp. 10, 385-390).  
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“…and you can't always depend on carers [to provide motivation] because carers 
have got a life as well, they've got, y'know they can't be there all the time because 
it's very, very stressful… [there is a need for]…Support. Other support. Extra 
support… Ehm, a service there that's what they actually do, that's what they focus 
on…” (HP1, pp. 6, l. 181-192).  
Carers commented on individual’s lack of insight into their illness, which has the 
potential to act as a barrier to engagement in therapy: 
“…patients may not refer to their illness as they don’t actually see themselves as 
being ill. That is something that's so important. [PwS] did not or does not see 
himself as a schizophrenic person…” (C3, pp. 3, l. 82-84).  
“…[weekly therapy sessions] No I don't think so. Because d'you know something 
they'll feel as though it’s a chore. They’re making me go here, they're making me go 
here… I've got to go there, I've got to go there, you know what I mean, as if, what's 
the matter that I’ve got to go there and nobody else has got to go there, y'know?...” 
(C2, pp. 255-261). 
 
Complexity 
Interplay of Positive and Negative Symptoms. The majority of carers and 
professionals commented on the complex interaction of positive and negative 
symptoms and how these may impact on interpreting social situations or in 
relation to challenging beliefs associated with positive symptoms: 
“…I notice on the train he would become upset he would become anxious ehm, I 
don’t know particularly what he was thinking, maybe he thought people were 
looking at him, maybe he felt ehm under pressure, and maybe he was becoming 
delusional because of this…” (C3, pp. 2, l. 70-74). 
“…[discussing social situations] especially people with psychosis because they can 
misinterpret situations really rapidly…” (HP4, pp.4, l. 130).  
“…somebody with a, a concrete belief [related to positive symptoms] might, might 
not be receptive to have that challenged…” (HP3, pp.5, l. 174). 
 
Sensitivity to Psychological Processes. All carers and professionals commented on 
various psychological factors adding to complexity in the treatment of negative 
symptoms. These included: 
Sensitivity to individual cognitive ability: 
 “…part of [PwS] trouble, another part of it, is eh, her forgetfulness, she’s very very 
very, very forgetful, bad memory…” (C1, pp. 10, l. 367-368).  
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“…people who’ve got a severe psychosis ehm, who may have cognitive deficits, who 
may have difficulty processing information, comprehending information…” (HP4, 
pp. 4, l. 114-116). 
Awareness of comorbidity: 
 “…very serious ehm psychotic illness, ehm diagnosed with schizophrenia, ehm, and 
he has autism as well…” (HP1 pp.5, 156-157). 
Consideration of other possible important psychological constructs to target 
through intervention:  
“…y'know, he lost a lot of his confidence…” (C2, pp. 2, l.52).  
“…y'know assertiveness and all that kinda stuff…that’s something as well where I 
think patients with schizophrenia that's not really focussed on... things like 
their…confidence in their own abilities…” (HP1, pp. 4, 143-146).  
 
Discussion 
The aim of this study was to improve understanding of psychosocial treatment 
needs for negative symptoms by obtaining the perspectives of major 
stakeholders – patients, carers, and healthcare professionals. The qualitative 
analysis and emergent themes provide important information related to 
treatment need, intervention planning, and implementation factors. 
Treatment Need 
A substantial finding from the present study is the need for future psychosocial 
interventions to be developed in line with recovery principles (Leamy et al, 
2011). The present subthemes of choice, values, and empowerment are 
consistent with Wallace et al’s (2016) findings from a recent exploration of 
patient experiences of a recovery-oriented complex intervention. Collaboration 
and respect are crucial in creating the right therapeutic environment across all 
stages of intervention and are important elements in an individual’s journey 
towards recovery. Future intervention development may need to consider 
methods to meet these needs.  
Hamman et al’s (2015) survey of psychiatrist’s opinions in relation to shared 
decision making with patients may provide a starting point for understanding 
how to meet this challenge. The survey indicated psychosocial aspects of 
treatment may be a key area for shared decision making. Patients in general value 
shared decision making (see Lester, Tritter, & England, 2003) and people who 
experience negative symptoms have specific treatment preferences (Moritz et al, 
2016). Shared decision making can tackle preference, collaboration and respect 
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in line with recovery. The importance of this is indicated in relation to the 
different patient preferences for treatment format in the current study.  
All carers and professionals commented on the need for a graded approach 
across all aspects of treatment.  For example, grading of goal setting, review of 
progress, and in deciding end point of treatment. This finding suggests a flexible 
and graded approach to measuring therapy ‘success’ which is at odds with the 
specific clinical/functional criteria recently suggested by Schooler et al (2015). 
This highlights the disparity in user-defined versus clinician-defined outcomes 
and understanding of recovery. 
 
Specific Intervention Targets 
The present findings support previous studies (e.g. Lasalvia et al, 2012) which 
suggest a lack of consensus amongst patients, carers, and healthcare 
professionals in relation to treatment priorities. Moritz et al’s (2016) study 
highlights that patients rate amotivation as a high priority target of intervention, 
which is consistent with patient’s comments in the present study. Furthermore, 
patient’s comments on medication being helpful may reflect a similar finding by 
Sterk et al (2013) in relation to patient satisfaction with medical treatment.  
However, patients may be so highly conditioned to the medical model of 
treatment that it is difficult for them to able to conceive of ‘treatment’ as anything 
other than a pill to take. One patient consistently referred to medication 
compliance which may be indicative of the way the medical model fosters an 
external locus of control in individuals which may subsequently impact on their 
illness beliefs and self-efficacy. It could also convey a message about the systemic 
attitude to negative symptoms in general. As noted by one healthcare 
professional, unhelpful attitudes towards negative symptoms exist across 
organisational systems, with staff at times mirroring negative symptoms (e.g. a 
sense of apathy in their approach to intervention). However, Elis et al (2013) 
highlight the role of medication in many of the reported helpful psychosocial 
treatments for negative symptoms, indicating a need to find a balance between 
medicine and psychosocial input in order to meet individual’s needs.  
There were different opinions amongst carers and professionals in relation to 
treatment offering development of skills to challenge thoughts and in developing 
positive communication techniques. These are key intervention ingredients for a 
number of psychosocial treatments for negative symptoms, such as Cognitive 
Behavioural Social Skills Training (CBSST; Granholm, Holden, Link & McQuaid, 
2014). This may indicate a need to further our understanding of treatment 
priority.  
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There was general agreement across both carers and professionals in relation to 
the complexity of treatment of negative symptoms. The theme of ‘complexity’ 
may be a reflection of the difficulties staff face (e.g. therapeutic pessimism) when 
dealing with negative symptoms. This may be a reason negative symptoms can 
be ignored or avoided as a treatment need. It is clear individuals can present with 
comorbid factors such as cognitive impairment or other mental health disorders. 
Healthcare professionals in the study identified the need for training in order for 
them to feel empowered and able to address complexity.  
It is also apparent that negative symptoms are transdiagnostic – that is they are 
common features of other mental disorders, such as depression (see Buckley et 
al, 2009). Carers and professionals in the present study commented on 
psychological targets that are not addressed in the treatment of schizophrenia 
(e.g. confidence). Moritz et al (2016) indicate that patients rated low self-esteem 
as the most urgently needed area for psychosocial intervention. This highlights 
two possible avenues of research. Firstly, research could begin to focus on single 
negative symptom using comprehensive assessment tools, such as the Zurich 
Negative Symptom Scale (Kaiser, 2016), to filter out specific symptoms at 
recruitment stages. Alternatively, a solution may be to develop a transdiagnostic 
approach to negative symptoms that can be applied across mental health 
disorders.   
Implementation  
Carers and professionals noted that patient lack of insight into their illness may 
act as a potential barrier to engagement. Patients also commented on their 
experience of low motivation to engagement, which may be a by-product of poor 
insight. Lysaker et al (2011a) indicate the role of metacognition in insight and 
more recently Buck et al (2014) suggest that individuals with poor metacognitive 
ability may be a barrier to overcoming negative symptoms. The current findings 
support the notion of developing patient metacognition as a first step to 
treatment.  
Both carers and healthcare professionals indicated a need for a systemic 
approach to raising awareness and understanding of negative symptoms, with 
one participant specifically noting unhelpful organisational attitudes. As noted in 
a recent review (Morera, Pratt, & Bucci, 2016) the medical model remains 
prominent in staff perspectives and can have a negative impact on their attitudes 
towards recovery. Le Boutillier et al (2015) draw attention to the disparity 
between clinical recovery, personal recovery, and service-defined recovery, the 
latter being driven by organisational factors. Patients consider professional 
attitudes important in the therapeutic process (Sterk et al, 2013) and this may be 
an area for organisational improvement. Staff may need to be trained to develop 
a better understanding of recovery.   
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Healthcare professionals in the present study also identified the need for specific 
training for working with negative symptoms, and for a shared vision across all 
levels of organisation in achieving this. This reflects findings of a review from 
Ince, Haddock, and Tai (2015) who highlighted the need for well-planned 
training for staff and commitment across organisational levels. Both carers and 
professionals in the present study commented that patients have a need for well-
timed interventions. The importance of this is indicated by one carer’s comment 
referring to missed opportunities of current interventions through their reactive 
approach to schizophrenia in general. It may be that a stepped-care model can 
address this issue through a proactive approach to treatment. For example, 
through stepping-up community input to deter crisis and subsequent hospital 
admissions.  
The identification of organisational resources as a barrier to treatment is 
consistent with the literature (Williams, Prillo, & Brown, 2015). Interventions do 
not happen in isolation and extra support outwith a treatment in the form of 
supportive scaffolding or social groups may be beneficial to maintain gains. Elis 
et al (2013) highlight the self-defeating approach of giving people the skills to 
adapt to social situations while in therapy, yet they may not have the opportunity 
to apply these in real life. Providing opportunity is a key aspect of behaviour 
change (see Michie, van Stralen, and West, 2011) which organisations may need 
to consider. However, this would require substantial resource and planning 
across organisations which should be informed by an ecological approach to 
implementation (Raghavan, Bright, & Shadoin, 2008) – specifically, integrated 
policymaking across political, organisation, regulatory and social levels that aims 
for successful and sustainable implementation of interventions.  
Strengths and Limitations 
To our knowledge this is the first study to utilise qualitative methods to 
understand the treatment preferences of major stakeholders in relation to 
negative symptoms.  The qualitative methodology allowed an in-depth 
exploration of these key stakeholder perspectives.  An interesting outcome of this 
research is related to the process of study recruitment.  Inpatients initially agreed 
to participate yet pulled out on the day. They may have felt overwhelmed by the 
interview process. Or this may reflect other deficits related to effort-based 
decision making (Treadway, Bossaller, Shelton, & Zald, 2012) or being able to 
foresee any benefits in taking part in the research (Treadway & Zald, 2013). 
Consideration should be given to these factors if this group are to be given a 
platform for their opinions to be heard. A more active approach to research 
recruitment should be employed in obtaining the perspectives of this particular 
group.  
Additionally, research could build upon the present findings by utilising 
quantitative methodologies (e.g. online survey) to capture the views of larger 
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representative numbers from each stakeholder group. It is acknowledged that 
the findings of the present study may not be representative of other people’s own 
personal experiences and views on negative symptoms and their treatment.  
 
 
Conclusions 
The study aimed to explore the views of key stakeholders in relation to negative 
symptoms and their treatment. The findings address gaps in the literature on 
psychosocial treatment of negative symptoms (e.g. Schooler at al, 2015) and also 
in attempting to generate knowledge about what patients value (Wykes, 2016).  
Themes suggest an individualised treatment consistent with recovery, set within 
a whole systems approach. This approach may best be framed in a stepped-care 
model of delivery. A number of implementation barriers were identified with 
solutions suggested. There may be scope in the development of a transdiagnostic 
approach to the treatment of negative symptoms to address the identified theme 
of complexity.  
Overall, no study to date has explored the opinions of major stakeholders in 
relation to treatment preferences. We have identified that patients may find 
engaging in research a challenging process and may experience difficulties in 
communication during research.  There remains a need for research to target this 
population to develop our understanding of their treatment preferences in 
working towards developing an evidence-based psychosocial intervention for 
negative symptoms.   
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2. Length  
All articles submitted to PAPT must adhere to the stated word limit for the particular 
article type. The journal operates a policy of returning any papers that are over this 
word limit to the authors. The word limit does not include the abstract, reference list, 
figures and tables. Appendices however are included in the word limit. The Editors 
retain discretion to publish papers beyond this length in cases where the clear and 
61 
 
concise expression of the scientific content requires greater length (e.g., a new theory 
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as deposited in the funding agency's preferred archive. For the full list of terms and 
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register and have their article automatically added to the system. Please ensure that a 
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tracking and for a wealth of resources including FAQs and tips on article preparation, 
submission and more.  
13. The Later Stages  
The corresponding author will receive an email alert containing a link to a web site. A 
working e-mail address must therefore be provided for the corresponding author. The 
proof can be downloaded as a PDF (portable document format) file from this site. 
Acrobat Reader will be required in order to read this file. This software can be 
downloaded (free of charge) from the following web site: 
http://www.adobe.com/products/acrobat/readstep2.html. This will enable the file to 
be opened, read on screen and annotated direct in the PDF. Corrections can also be 
supplied by hard copy if preferred. Further instructions will be sent with the proof. 
Hard copy proofs will be posted if no e-mail address is available. Excessive changes 
made by the author in the proofs, excluding typesetting errors, will be charged 
separately.  
14. Early View  
Psychology and Psychotherapy is covered by the Early View service on Wiley Online 
Library. Early View articles are complete full-text articles published online in advance 
of their publication in a printed issue. Articles are therefore available as soon as they 
are ready, rather than having to wait for the next scheduled print issue. Early View 
articles are complete and final. They have been fully reviewed, revised and edited for 
publication, and the authors’ final corrections have been incorporated. Because they 
65 
 
are in final form, no changes can be made after online publication. The nature of Early 
View articles means that they do not yet have volume, issue or page numbers, so they 
cannot be cited in the traditional way. They are cited using their Digital Object 
Identifier (DOI) with no volume and issue or pagination information. E.g., Jones, A.B. 
(2010). Human rights Issues. Human Rights Journal. Advance online publication. 
doi:10.1111/j.1467-9299.2010.00300.x 
 
 
  
66 
 
Appendix 1.2: Details of Excluded Studies 
Table 1 provides examples of prominent systematic reviews and treatment 
studies that were considered for final inclusion but failed to meet specific 
inclusion criteria.  
Table 1: Examples of Excluded Studies 
Reference Reason for Exclusion 
 
Dickerson, F. B., & Lehman, A. F. (2006). Evidence-
based psychotherapy for schizophrenia. The Journal 
of nervous and mental disease, 194(1), 3-9. 
 
 Explicit reference to sub-domains of 
negative symptoms was not included in 
results analysis. 
  
 
Gold, C., Solli, H. P., Krüger, V., & Lie, S. A. (2009). 
Dose–response relationship in music therapy for 
people with serious mental disorders: Systematic 
review and meta-analysis. Clinical psychology 
review, 29(3), 193-207. 
 
 
 Explicit description of music therapy not 
included.  
 Explicit reference to sub-domains of 
negative symptoms was not included in 
results analysis. 
 
Mairs, Hilary, Karina Lovell, and Philip Keeley. 
"Carer and mental health professional views of a 
psychosocial treatment for negative symptoms in 
psychosis: A qualitative study." International journal 
of nursing studies 49.10 (2012): 1191-1199. 
 
 
 Explicit reference to sub-domains of 
negative symptoms was not included in 
results analysis. 
 
Mairs, H., Lovell, K., Campbell, M., & Keeley, P. 
(2011). Development and pilot investigation of 
behavioral activation for negative symptoms. 
Behavior modification, 35(5), 486-506. 
 
 
 Explicit reference to sub-domains of 
negative symptoms was not included in 
results analysis. 
 
 
Perivoliotis, D., & Cather, C. (2009). Cognitive 
behavioral therapy of negative symptoms. Journal of 
clinical psychology, 65(8), 815-830. 
 
 The description of neurocognitive 
assessment of case study indicated 
historical attentional problems. Early years 
assessments did not confirm ADHD. 
However, it was unclear if case study 
neuropsychological impairments were 
closely linked with schizophrenia or a long 
standing separate neurological deficit. 
Therefore a decision was made to exclude 
due to generalisability issues. 
  
 
Staring, A. B., ter Huurne, M. A. B., & van der Gaag, M. 
(2013). Cognitive behavioral therapy for negative 
symptoms (CBT-n) in psychotic disorders: a pilot 
study. Journal of behavior therapy and experimental 
psychiatry, 44(3), 300-306. 
 
 
 
 Explicit reference to sub-domains of 
negative symptoms was not included in 
results analysis. 
 
  
67 
 
Appendix 2.1: Patient Interview Script and Questions 
There are many treatments that have been shown to be effective for common problems of schizophrenia. These 
treatments tend to focus on hallucinations and delusional thinking, known as positive symptoms. However, there 
is little known about effective psychological treatments for the negative symptoms of schizophrenia.  
These symptoms, known as negative symptoms, can include experiencing a lack of motivation, not looking 
forward to things, feeling emotionally flat, or feeling disinterested in having social interactions with other people. 
These problems can be a barrier to recovery and can stop people living the life they would like to.  
This interview will ask questions about specific factors related to the psychological treatment of these negative 
symptoms. We are interested in your opinion of these psychological treatments.  
 
Effective psychosocial components 
There are common factors in the treatments that have been shown to be helpful for these symptoms.  
Q1. Based on your own experience, how important would it be for you for a treatment to provide information 
specific to schizophrenia and negative symptoms? (prompt use the above problems to describe negative 
symptoms if needed) 
Follow-up… How important would it be for you for a psychological treatment to provide information about how 
the treatment works?  
Q2. Based on your own experience, how important would it be for you to receive training in problem solving skills 
for: 
1. Everyday problems? (prompt such as planning a shopping trip, handling money and bills, looking for a 
job, using public transport)? 
 
2. Understanding social situations? (prompt For instance, to help in understanding what yourself and 
others are thinking and feeling).  
Q3. Based on your own experience, how important would it be to you for a treatment to help develop your 
ability to communicate to others when you feel positive emotions? 
 
Q4. Based on your own experience, how important would it be to you for a treatment to help you develop skills 
in setting realistic goals and supporting you to achieve these goals? 
 
Q5. Based on your own experience, how important would it be to you to be encouraged to practice the skills 
learned in therapy? 
 
Q6. Based on your own experience, how important would it be to you for a treatment to develop skills that 
would help you to challenge the beliefs that may be holding you back from things you want to do? 
Delivery 
The treatments that have been shown to be helpful tend to be delivered in different ways and in different 
settings. 
Format 
Q7. For you, based on your own experience, can you comment on the idea of being part of a group receiving a 
treatment for negative symptoms? 
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 Follow-up… Would the number of people in a treatment group be important to you? 
 Follow-up… Other treatments are delivered in a 1-2-1 format with the therapist and client, can you 
comment on this idea?  
Sessions 
Q8. The treatments that have been shown to be helpful tend to last between 1-2 hours….How important is the 
duration of treatment sessions for you?  
 Follow-up… Therapy sessions tend to be delivered weekly…from your own experience, how important 
is this for you? 
 
 Follow-up… Based on your own experience, what would be the suitable number of sessions a 
treatment should aim to finish in? 
 
The treatments that have been shown to be helpful tend to be delivered in different settings and these can 
include clinical settings, community settings such as local GP clinics, the client’s home, or as part of routine care 
for people in hospital settings.  
Q9. From your own experience, how important is the setting in which a treatment takes place? 
Therapists 
The treatments that have been shown to be helpful tend to be delivered by different professionals. Some are 
delivered by people such as psychologists and psychiatrists. Others treatments are delivered by nurses, family 
therapists, or social workers.  
Q10. Based on your own experience, how important to you is it that treatments are delivered by a particular 
professional? 
Implementation 
Q11. Based on your own experience, do you have any ideas of what might get in the way of treating negative 
symptoms? 
Open ended section 
Q12. Based on your own personal experience, is there anything else about treating negative symptoms you 
would like to comment on? 
Prompt –  
 Please remember, the focus of this interview is to get your opinion on treatment factors 
for problems like feeling emotionally flat, having low motivation, or feeling disinterested 
in communicating with others.  These are known as negative symptoms.  
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Appendix 2.2: Interview Script and Questions  
(Carer and Professional Carer Version) 
There are many treatments that have been shown to be effective for common problems of schizophrenia. These 
treatments tend to focus on hallucinations and delusional thinking, known as positive symptoms. However, there 
is little known about effective psychological treatments for the negative symptoms of schizophrenia.  
These symptoms, known as negative symptoms, can include experiencing a lack of motivation, not looking 
forward to things, feeling emotionally flat, or feeling disinterested in having social interactions with other people. 
These problems can be a barrier to recovery and can stop people living the life they would like to.  
This interview will ask questions about specific factors related to the psychological treatment of these negative 
symptoms. From your experience of caring for someone who experiences negative symptoms, we are interested 
in your opinion of these psychological treatments.  
Effective psychosocial components 
There are common factors in the treatments that have been shown to be helpful for these symptoms.  
Q1. Based on your own experience, how important would it be for you for a treatment to provide education 
specific to schizophrenia and negative symptoms? (prompt use the above problems to describe negative 
symptoms if needed) 
Follow-up… How important would it be for you for a psychological treatment to provide education about how the 
treatment works?  
Q2. Based on your own experience, how important would it be for you for a treatment to include training in 
problem solving skills for: 
3. Everyday problems? (prompt such as planning a shopping trip, handling money and bills, looking for a 
job, using public transport)? 
 
4. Understanding social situations? (prompt For instance, to help the person understand what they and 
others are thinking and feeling).  
Q3. Based on your own experience, how important would it be to you for a treatment to develop skills in helping 
people to communicate to others when they feel positive emotions? 
 
Q4. Based on your own experience, how important would it be to you for a treatment to develop skills in setting 
realistic goals and in being supported to achieve these goals? 
 
Q5. Based on your own experience, how important would it be for a treatment to encourage people to practice 
the skills learned in therapy? 
 
Q6. Based on your own experience, how important would it be to you for a treatment to develop skills that 
would help people to challenge the beliefs that may be holding them back from things they want to do? 
Delivery 
The treatments that have been shown to be helpful tend to be delivered in different ways and in different 
settings. 
Format 
Q7. Based on your own experience, can you comment on the idea of group therapy for people receiving a 
treatment for negative symptoms? 
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 Follow-up… Would the number of people in a treatment group be important? 
 Follow-up… Other treatments are delivered in a 1-2-1 format with the therapist and client, can you 
comment on this idea?  
Sessions 
Q8. The treatments that have been shown to be helpful tend to last between 1-2 hours….How important is the 
duration of treatment sessions?  
 Follow-up… Therapy sessions tend to be delivered weekly…from your own experience, how important 
is this? 
 
 Follow-up… What would be the suitable number of sessions a treatment should aim to finish in? 
 
The treatments that have been shown to be helpful tend to be delivered in different settings and these can 
include clinical settings, community settings such as local GP clinics, the client’s home, or as part of routine care 
for people in hospital settings.  
Q9. From your own experience, how important is the setting in which a treatment takes place? 
Therapists 
The treatments that have been shown to be helpful tend to be delivered by different professionals. Some are 
delivered by people such as psychologists or psychiatrists. Others treatments are delivered by nurses, family 
therapists, or social workers.  
Q10. Based on your own experience, how important to you is it that treatments are delivered by a particular 
professional? 
Implementation 
Q11. Based on your own experience, do you have any ideas of what might get in the way of treating negative 
symptoms? 
Open ended section 
Q12. Based on your own personal experience, is there anything else about treating negative symptoms you 
would like to comment on? 
Prompt – Please remember, the focus of this interview is to get your opinion on treatment factors for problems 
like feeling emotionally flat, having low motivation, or feeling disinterested in communicating with others.  These 
are known as negative symptoms.  
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Appendix 2.3: Information and Consent for Future Information Events 
 
Centre Number: 
Project Number: 
Subject Identification Number for this trial: 
INFORMATION AND CONSENT FORM 
 
People who have taken part in this study are being asked if they would like to act as consultants on future 
research that effects people with severe and enduring mental illness. Specifically you are asked if you 
would consent to: 
1. Being informed of upcoming events related to psychosocial treatments. 
2. Being invited to attend these events to provide input based on your own personal experience.  
 
If you are interested in this please provide your name and contact details below and enclose in the 
envelope provided. This will be kept with the clinical care team who will contact you with information 
related to upcoming events. This will be stored in accordance with NHS policy.  
 
Name:……………………………………………………………….. 
 
Contact details (email or phone): 
………………………………………………………………………….. 
………………………………………………………………………….. 
    Please 
initial box 
 
I confirm that I have read and understand the above information sheet  
have had the opportunity to ask questions. 
 
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my legal rights being affected. 
 
I agree to being informed, and invited to, these upcoming events. 
       
 
           
Name Date Signature 
 
 
 
(1 copy for participant) 
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Appendix 2.4: Participant - Information Sheet 
Study Title: 
Treatment of negative symptoms in schizophrenia: An exploration of key stakeholders 
views on treatment gap, intervention, and recovery. 
Brief Summary: 
Symptoms of schizophrenia can include difficulties with motivation, reduced emotional 
expressiveness, and low interest in activities. These symptoms can be particularly 
burdensome but there is a lack of understanding about the best approach to treatment. 
In order to develop better treatments, this study invites people to participate in a one-
to-one interview with a researcher to discuss their views about these symptoms of 
schizophrenia and their treatment.  
Who is conducting the research?  
This study is being carried out by Phil Smith and is supervised by Dr Hamish McLeod 
(University of Glasgow) and Dr. Polash Shajahan  (NHS Lanarkshire).  
Invitation  
You are being invited to take part in a research study. Before you decide if you would 
like to take part it is important for you to understand why the research is being done and 
what it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. It is important that you take the time you need to 
decide whether or not you wish to take part. 
What is the purpose of the study?  
Symptoms such as difficulties with motivation, reduced emotional expression, and a 
low interest in activities (known as negative symptoms) can be burdensome for people 
who experience schizophrenia. This study seeks to improve our understanding of 
treating these symptoms. We are consulting people with experience in order to gather 
vital information that can be used to improve the treatments we offer in health service 
settings. 
The current study aims to explore this by inviting people who have experience of 
negative symptoms to participate in an interview to provide their views on these 
symptoms and their treatment. Your involvement in the study will last for the duration 
of the interview (approx 30 minutes). The study will be submitted as part of Phil 
Smith’s Doctorate in Clinical Psychology research portfolio.  
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We would also like to seek consent from people to be invited as consultants on future 
research that affects people with severe and enduring mental health issues.  This would 
involve you providing consent to being told about upcoming events related to 
psychosocial treatments which you would be invited to attend to provide input from 
your own personal experience. This will be discussed further at the interview debrief, 
where questions can be asked and consent forms provided if interested.  
Why have I been chosen? 
You may currently experience/ have past experience of negative symptoms of 
schizophrenia.  
Do I have to take part?  
It is entirely up to you to decide whether or not to take part. If you opt in, you will be 
asked to sign a consent form. You are free to withdraw at any time and without giving a 
reason. Regardless of whether you decided to participate or not, it will not affect the 
treatment that you receive. 
What will happen to me if I take part?  
You will be invited to attend a single interview with the researcher which will last 
approximately 30 minutes. This will take place in a private room within the ward. You 
will be asked your opinions about the negative symptoms of schizophrenia and their 
treatment. The interviews will be audio recorded so that they can be transcribed for 
analysis. Any direct quotes used in the final written version of the study will be 
anonymized. You will have an opportunity to ask questions about the study.  
What are the possible disadvantages and risk of taking part? 
Some people may find that the interviews address sensitive issues. But, there is no plan 
to intentionally ask distressing or upsetting questions. 
What are the possible benefits of taking part?  
You will receive no direct incentives or rewards from taking part in this study. The 
information you provide will give us a better understanding of negative symptoms and 
their treatment. This will help to inform the development of new interventions for 
negative symptoms.  
Will my taking part in this study be kept confidential? 
All information collected about you and the things you say during the research will be 
kept strictly confidential. Your study records will be identified only by an ID number 
and any personal identifying information (e.g. name, address) will be concealed. 
Confidentiality will be strictly maintained unless we detect that there is evidence of 
serious harm or risk of serious harm to any person. In such cases we may have an 
obligation to contact relevant statutory bodies/agencies. Where possible we will 
discuss this action with you ahead of time. As part of routine regulation qualified NHS 
regulators may audit research projects to ensure quality is being maintained. 
What will happen to the results of the study?  
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The results of the study will be written into a thesis and submitted to the University of 
Glasgow as part of the main researcher’s (Phil Smith) requirements for the Doctorate in 
Clinical Psychology. A summary of this report will be sent to Dr. Polash Shajahan for 
distribution to participants. This report is expected to be completed by August 2016. 
The overall results of the research may also be submitted for publication in a scientific 
journal. No individual will be identifiable from any published work.  
Who is organizing and funding this research? 
The research is organised by the University of Glasgow and supported by NHS 
Lanarkshire. There is no funding associated with this research. 
Who has reviewed the study? 
All research in the NHS is scrutinized by an independent group of people called a 
Research Ethics Committee to protect your interests. This study has been reviewed by 
the West of Scotland Ethics Committee Service (WoSRES) and favorable opinion has 
been given. 
If you have any further questions 
If you would like more information about the study and wish to speak with someone 
who is independent of the research team, please contact Dr Sue Turnbull, Research 
Tutor, University of Glasgow, email: s.turnbull@glasgow.ac.uk, Tel no: 0141 
2113937 
If you have a complaint about any aspect of the study 
If you are unhappy about any aspect of the study and wish to make a complaint, please 
contact the researcher in the first instance but the normal NHS complaint procedure is 
also available for you. The contact person for making a complaint in NHS Lanarkshire is: 
Laura Jack, NHS Lanarkshire Headquarters, Kirklands Hospital, Fallside Road, 
Bothwell, G71 8BB, Tel: 01698 858321, Email: 
laura.bryan@lanarkshire.scot.nhs.uk 
Contact details - If you would like further information, you can contact:  
Main Researcher (Trainee Clinical Psychologist): 
Phil Smith       
University of Glasgow 
Institute of Health and Wellbeing 055 Great Western Road 
Glasgow, G12 0XH 
p.smith.4@research.gla.ac.uk
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Appendix 2.5: Carer - Participant Information Sheet 
Study Title: 
Treatment of negative symptoms in schizophrenia: An exploration of key stakeholders views on treatment 
gap, intervention, and recovery. 
Brief Summary: 
Symptoms of schizophrenia can include difficulties with motivation, reduced emotional expressiveness, 
and low interest in activities. These symptoms can be particularly burdensome but there is a lack of 
understanding about the best approach to treatment. In order to develop better treatments, this study 
invites people to participate in a one-to-one interview with a researcher to discuss their views about these 
symptoms of schizophrenia and their treatment.  
Who is conducting the research?  
This study is being carried out by Phil Smith and is supervised by Dr Hamish McLeod (University of 
Glasgow) and Dr. Ian-Mark Kevan (NHS GG&C).  
Invitation  
You are being invited to take part in a research study. Before you decide if you would like to take part it is 
important for you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. It is important that you 
take the time you need to decide whether or not you wish to take part. 
What is the purpose of the study?  
Symptoms such as difficulties with motivation, reduced emotional expression, and a low interest in 
activities (known as negative symptoms) can be burdensome for people who experience schizophrenia. 
This study seeks to improve our understanding of treating these symptoms. We are consulting people with 
experience in order to gather vital information that can be used to improve the treatments we offer in 
health service settings. 
We are inviting carers and/or family members of someone with experience of the above symptoms to 
participate in an interview. During the interview people can share their experience and provide their views 
on treatment for these symptoms. Your involvement in the study will last for the duration of the interview 
(approximately 30 minutes). 
The study will be submitted as part of Phil Smith’s Doctorate in Clinical Psychology research portfolio.  
Why have I been chosen? 
We asked health service staff to approach people who have experience of caring for someone who 
currently, or previously, has experienced negative symptoms of schizophrenia.  
Do I have to take part?  
It is entirely up to you to decide whether or not to take part. If you opt in, you will be asked to sign a consent 
form. You are free to withdraw at any time and without giving a reason. Regardless of whether you decided 
to participate or not, it will not affect the treatment that your loved one or family member receives now or 
in the future. 
What will happen to me if I take part?  
You will be invited to attend a single interview with the researcher which will last approximately 30 
minutes. This will take place in a private room within the ward. You will be asked your opinions about the 
negative symptoms of schizophrenia and their treatment. The interviews will be audio recorded so that 
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they can be transcribed for analysis. Any direct quotes used in the final written version of the study will be 
anonymized. You will have an opportunity to ask questions about the study.  
What are the possible disadvantages and risk of taking part? 
Some people may find that the interviews address sensitive issues. But, there is no plan to intentionally ask 
distressing or upsetting questions. 
What are the possible benefits of taking part?  
You will receive no direct incentives or rewards from taking part in this study. The information you provide 
will give us a better understanding of negative symptoms and their treatment. This will help to inform the 
development of new interventions for negative symptoms.  
Will my taking part in this study be kept confidential? 
All information collected about you and the things you say during the research will be kept strictly 
confidential. Your study records will be identified only by an ID number and any personal identifying 
information (e.g. name, address) will be concealed. Confidentiality will be strictly maintained unless we 
detect that there is evidence of serious harm or risk of serious harm to any person. In such cases we may 
have an obligation to contact relevant statutory bodies/agencies. Where possible we will discuss this action 
with you ahead of time. As part of routine regulation qualified NHS regulators may audit research projects 
to ensure quality is being maintained. 
What will happen to the results of the study?  
The results of the study will be written into a thesis and submitted to the University of Glasgow as part of 
the main researcher’s (Phil Smith) requirements for the Doctorate in Clinical Psychology. A summary of 
this report will be sent to Dr. Ian-Mark Kevan for distribution to participants. This report is expected to be 
completed by August 2016. The overall results of the research may also be submitted for publication in a 
scientific journal. No individual will be identifiable from any published work.  
Who is organizing and funding this research? 
The research is organised by the University of Glasgow and supported by NHS GG&C. There is no direct 
funding of this research. 
Who has reviewed the study? 
All research in the NHS is scrutinized by an independent group of people called a Research Ethics 
Committee to protect your interests. This study has been reviewed by the West of Scotland Ethics 
Committee Service (WoSRES) and favorable opinion has been given. 
If you have any further questions 
If you would like more information about the study and wish to speak with someone who is independent 
of the research team, please contact Dr Sue Turnbull, Research Tutor, University of Glasgow, email: 
s.turnbull@glasgow.ac.uk, Tel no: 0141 2113937 
If you have a complaint about any aspect of the study 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact the 
researcher in the first instance but the normal NHS complaint procedure is also available for you from the 
following internet address:  
http://www.nhsggc.org.uk/get-in-touch-get-involved/complaints/ 
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Contact details 
If you would like further information, you can contact:  
 
Main Researcher (Trainee Clinical Psychologist): 
Phil Smith    
   
University of Glasgow 
Institute of Health and Wellbeing 
Admin Building 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow, G12 0XH 
p.smith.4@research.gla.ac.uk 
 
 
Research Supervisors:     
  
Dr Hamish McLeod 
University of Glasgow  
Institute of Health and Wellbeing 
Admin Building 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow, G12 OXH   
   
hamish.mcLeod@glasgow.ac.uk  
 
Field Supervisor: Dr. Ian-Mark Kevan 
Consultant Clinical Psychologist, NHS Greater Glasgow & Clyde  
Gartnavel Royal Hospital 
1055 Great Western Rd, Glasgow G12 0XH 
 
IanMark.Kevan@ggc.scot.nhs.uk   
 
 
 
Thank you for taking the time to read this information sheet. 
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Appendix 2.6: Healthcare Professional - Participant Information Sheet 
Study Title: 
Treatment of negative symptoms in schizophrenia: An exploration of key stakeholders views on treatment gap, 
intervention, and recovery. 
Brief Summary: 
Symptoms of schizophrenia can include difficulties with motivation, reduced emotional expressiveness, and 
low interest in activities. These symptoms can be particularly burdensome but there is a lack of understanding 
about the best approach to treatment. In order to develop better treatments, this study invites people to 
participate in a one-to-one interview with a researcher to discuss their views about these symptoms of 
schizophrenia and their treatment.  
Who is conducting the research?  
This study is being carried out by Phil Smith and is supervised by Dr Hamish McLeod (University of Glasgow) and 
Dr. Polash Shajahan (NHS Lanarkshire).  
Invitation  
You are being invited to take part in a research study. Before you decide if you would like to take part it is 
important for you to understand why the research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it with others if you wish. It is important that you take the 
time you need to decide whether or not you wish to take part. 
What is the purpose of the study?  
Symptoms such as difficulties with motivation, reduced emotional expression, and a low interest in activities 
(known as negative symptoms) can be burdensome for people who experience schizophrenia. This study seeks 
to improve our understanding of treating these symptoms. We are consulting people with experience in order 
to gather vital information that can be used to improve the treatments we offer in health service settings. 
We are inviting healthcare professionals with experience of caring for someone who experiences negative 
symptoms to participate in an interview where they can provide their views on symptoms and treatment. Your 
involvement in the study will last for the duration of the interview (approximately 30 minutes). The study will 
be submitted as part of Phil Smiths Doctorate in Clinical Psychology research portfolio.  
The study will be submitted as part of Phil Smiths Doctorate in Clinical Psychology research portfolio.  
Why have I been chosen? 
You may be a healthcare professional with experience of caring for someone who currently experiences/ has 
past experience of negative symptoms of schizophrenia.  
Do I have to take part?  
It is entirely up to you to decide whether or not to take part. If you opt in, you will be asked to sign a consent 
form. You are free to withdraw at any time and without giving a reason.  
What will happen to me if I take part?  
You will be invited to attend a single interview with the researcher which will last approximately 30 minutes. 
This will take place in a private room within the ward. You will be asked your opinions about the negative 
symptoms of schizophrenia and their treatment. The interviews will be audio recorded so that they can be 
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transcribed for analysis. Any direct quotes used in the final written version of the study will be anonymized. 
You will have an opportunity to ask questions about the study.  
What are the possible disadvantages and risk of taking part? 
Some people may find that the interviews address sensitive issues. But, there is no plan to intentionally ask 
distressing or upsetting questions. 
What are the possible benefits of taking part?  
You will receive no direct incentives or rewards from taking part in this study. The information you provide will 
give us a better understanding of negative symptoms and their treatment. This will help to inform the 
development of new interventions for negative symptoms.  
Will my taking part in this study be kept confidential? 
All information collected about you and the things you say during the research will be kept strictly confidential. 
Your study records will be identified only by an ID number and any personal identifying information (e.g. 
name, address) will be concealed. Confidentiality will be strictly maintained unless we detect that there is 
evidence of serious harm or risk of serious harm to any person. In such cases we may have an obligation to 
contact relevant statutory bodies/agencies. Where possible we will discuss this action with you ahead of time. 
As part of routine regulation qualified NHS regulators may audit research projects to ensure quality is being 
maintained. 
What will happen to the results of the study?  
The results of the study will be written into a thesis and submitted to the University of Glasgow as part of the 
main researcher’s (Phil Smith) requirements for the Doctorate in Clinical Psychology. A summary of this report 
will be sent to Dr. Polash Shajahan for distribution to participants. This report is expected to be completed by 
August 2016. The overall results of the research may also be submitted for publication in a scientific journal. No 
individual will be identifiable from any published work.  
Who is organizing and funding this research? 
The research is organised by the University of Glasgow and supported by NHS Lanarkshire. There is no funding 
associated with this research. 
Who has reviewed the study? 
All research in the NHS is scrutinized by an independent group of people called a Research Ethics Committee to 
protect your interests. This study has been reviewed by the West of Scotland Ethics Committee Service (WoSRES) 
and favorable opinion has been given. 
If you have any further questions 
If you would like more information about the study and wish to speak with someone who is independent of the 
research team, please contact Dr Sue Turnbull, Research Tutor, University of Glasgow, email: 
s.turnbull@glasgow.ac.uk, Tel no: 0141 2113937 
If you have a complaint about any aspect of the study 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact the researcher 
in the first instance but the normal NHS complaint procedure is also available for you. The contact person for 
making a complaint in NHS Lanarkshire is: Laura Jack, NHS Lanarkshire Headquarters, Kirklands Hospital, 
Fallside Road, Bothwell, G71 8BB, Tel: 01698 858321, Email: laura.bryan@lanarkshire.scot.nhs.uk 
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Contact details 
If you would like further information, you can contact:  
Main Researcher (Trainee Clinical Psychologist): 
Phil Smith       
University of Glasgow 
Institute of Health and Wellbeing 
1055 Great Western Road 
Glasgow, G12 0XH 
p.smith.4@research.gla.ac.uk 
 
Research Supervisor:   
Dr Hamish McLeod 
University of Glasgow  
Institute of Health and Wellbeing 
1055 Great Western Road 
Glasgow, G12 OXH      
Hamish.McLeod@Glasgow.ac.uk  
 
Field Supervisor: 
Dr. Polash Shajahan 
Consultant Psychiatrist, NHS Lanarkshire Bellshill Community Health Clinic 
Greenmoss Place 
Bellshill, ML4 1PS 
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Appendix 2.7: Study Information Letter 
Dear Sir/Madam, 
 
We are contacting you to inform you of a current research study you may be interested 
in. We are recruiting participants for our study entitled: Treatment of negative 
symptoms in schizophrenia: An exploration of key stakeholders views on 
treatment gap, intervention, and recovery. This study is being carried out at Bellshill 
Community Health Centre and Kelvin House, Gartnavel Royal Hospital.  
Negative symptoms of schizophrenia include difficulties with motivation, reduced 
emotional expressiveness, and low interest in activities. The negative symptoms of the 
illness can be particularly burdensome for people who experience schizophrenia and 
those who care for them. However, there is a lack of understanding about the best 
approach to treatment. In order to develop better treatments, this study invites people 
to participate in a one-to-one interview with a researcher to discuss their views about 
the negative symptoms of schizophrenia.   
An information sheet has been enclosed with further details of the study and contact 
details for the researcher.  
Thank you for taking the time to read this information.  I look forward to hearing from 
you.  
Yours sincerely, 
Phil Smith 
Trainee Clinical Psychologist 
College of Medical, Veterinary and Life 
Sciences 
University of Glasgow 
 
Email: p.smith.4@research.gla.ac.uk  
Research Supervisor: Dr Hamish McLeod 
University of Glasgow  
Institute of Health and Wellbeing 
1055 Great Western Road, Glasgow, G12 
OXH      
Hamish.McLeod@Glasgow.ac.uk
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Appendix 2.8: West of Scotland Research Ethics Service Letter 
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Appendix 2.9: NHS Lanarkshire R&D Approval Letter 
 
  
 
 
84 
 
Appendix 2.10: NHS GG&C R&D Approval Letter
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Appendix 2.11: Major Research Proposal 
 
Appendix 2.11: Major Research Proposal 
 
 
MRP –Proposal  
 
Philip Smith 
2109094S 
 
 
University Supervisor: Dr. Hamish McLeod 
Field Supervisor: Dr. Polash Shajahan 
 
Submission Date: 16.03.2015 
 
Version 2 
 
Word Count: 3,305  
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Title: Treatment of negative symptoms in schizophrenia: An exploration of key 
stakeholders views on treatment gap, intervention, and recovery. 
 
Abstract: 
Background: Negative symptoms can impact on therapeutic outcomes for patients 
experiencing schizophrenia. Up to 30% of people with a diagnosis of chronic 
schizophrenia exhibit negative symptoms yet there remains a gap in knowledge of 
effective negative symptom treatment.  Psychosocial interventions show positive gains 
for patients yet the variance in outcomes across studies may indicate a lack of 
coherence in intervention formulation. Implementation science provides insight into 
the intricate nature of intervention development and successful integration to everyday 
practice. Canvassing the views of any recipients of an intervention can have a beneficial 
impact on its development and implementation. Utilising this approach may provide 
insight into negative symptom treatment.   
Aims: To explore key stakeholder perceptions of negative symptoms and their 
treatment and the barriers/facilitators to the implementation of a new treatment 
intervention in a mental health setting. 
Methods: A qualitative design incorporating semi-structured interviews will be 
employed. Data will be analysed utilising thematic analysis.  
Applications: The data will form the basis for an initial first round Delphi process where 
a group of experts will be tasked with obtaining consensus views on a psychological 
treatment for negative symptoms. 
 
Introduction 
Negative Symptoms 
Negative symptoms in schizophrenia are part of a discrete domain separate from other 
common features of the illness (Foussias and Remington, 2010). Difficulties exist in 
differentiating primary negative symptoms (i.e. illness related) from secondary 
symptoms (related to treatment factors or the experience of psychosis itself).   Primary 
negative symptoms are further divisible into two separate sub-domains, that of 
diminished experience and amotivation/restricted expression (Favrod et al, 2014). 
These sub-domains consist of affective flattening, alogia, avolition, asociality and 
anhedonia (Foussias et al, 2014). Foussias and Remington (2010) state the estimated 
prevalence rates of negative symptoms are 25-30% in chronic schizophrenia. The 
severity of these symptoms can impact on therapeutic outcomes for patients 
experiencing schizophrenia (Foussias et al, 2014), yet White et al (2013) highlight a lack 
of activity in developing effective treatments to tackle these symptoms.  
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It may be that disparity amongst clinicians and researchers in relation to the notion of 
recovery (e.g. Slade, 2012) adds to the lack of activity in developing effective 
treatments. Recent years have seen the evolution of the recovery movement in mental 
illness. The CHIME conceptual framework (Leamy et al 2011) highlights a greater 
emphasis on idiosyncratic outcomes (i.e. personal meaning) as opposed to typical 
nomothetic outcomes reported in studies focussing on ‘clinical recovery’. For instance, a 
recent systematic review indicates the literature on recovery in negative symptoms 
tends to focus on symptomatic reduction and/or functional outcomes (see Valencia et 
al, 2014). This disparity indicates a need for research to explore treatment targets and 
outcomes most relevant to patients.  
In addition to this, Schooler et al (in press) draw attention to the lack of clarity “in the 
assessment of and meaningful improvement in negative symptoms…” This lack of clarity 
is related to the numerous factors involved in ascertaining what constitutes clinical 
relevance. For instance, carer burden is a well documented area related to 
schizophrenia but carers may have a different view on relevance than both clinicians 
and patients. Therefore, this current lack of clarity may impact on the development of 
effective interventions.  
Utilising a clinician-researcher consensus panel, Schooler et al (in press) provide a set of 
criteria upon which therapeutic impact on negative symptoms can be measured. There 
is a specific focus on symptom remission (or decrease in intensity) and functional 
outcomes.  However, this does not seem to fit the framework and ideas fuelling the 
current recovery movement.  Additionally, as the authors note, key stakeholders (e.g. 
patients, professional/ family carers, and policy makers) were not included in the panel. 
Future research needs to address this if a robust definition of negative symptoms and 
related treatment outcome is to be obtained. Furthermore, this lack of a universally 
agreed definition draws attention to the gap in current knowledge on negative symptom 
treatment.  
 
 
Intervention 
Elis et al (2013) provide a comprehensive review of psychosocial treatments for 
negative symptoms. Elis et al focus on three types of intervention – cognitive 
behavioural therapy (CBT), social skills training (SST) and combined treatment 
interventions. The review specifies that psychosocial treatments have the potential to 
alleviate negative symptoms. Yet, the variance in outcomes (e.g. maintenance factors at 
follow up) across each treatment may indicate the lack of a clear formulation on how 
best to intervene. Furthermore, there is clear evidence that outcomes are impacted by 
the type of intervention (e.g. individual versus group therapy, length of treatment, and 
the particular therapeutic focus).  
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This is further complicated when considering people with schizophrenia are thought to 
experience poor insight into their illness (Lysaker et al, 2011a) and may struggle with 
metacognition in general  (Lysaker et al, 2011b). Specifically, they may struggle to 
understand themselves and the people around them, making psychotherapy a difficult 
process to engage in.  
Additionally, variability of psychosocial intervention efficacy may be related to the co-
morbidity of other psychiatric illnesses (e.g. major depressive disorder) in people 
experiencing negative symptoms (Buckley et al, 2009). Foussias et al (2014) also 
suggest that while negative symptoms may be present in other disorders, people with 
schizophrenia may experience more enduring negative symptoms in the course of their 
illness. This indicates that new conceptualisations of negative symptom treatment need 
to consider transdiagnostic processes and co-morbidity.  
Lysaker et al, (2010) detailed two specific inter-related areas (i.e. self experience 
personal narrative and metacognition) future psychotherapy could address. 
Additionally, one line of future research stated is the “need for...the development of 
manualised treatments which could be tested for feasibility and effectiveness in 
randomised control trials” (Lysaker et al, 2010). However, the literature indicates that a 
number of empirically formulated interventions are not implemented successfully in 
everyday clinical settings (Durlak & Dupree, 2008).  
 
Intervention, Implementation and Patient and Public Involvement (PPI) 
Implementation science is an emerging science focussing on how and why a new 
practice is successfully adopted by organisations. A generally accepted notion in this 
field of science indicates that despite the development of effective interventions many 
are not successfully implemented into routine practice. This issue has become a focus of 
scientific enquiry and in recent years guidelines have been developed to aid in the 
formulation, development and delivery of complex interventions.   
The Medical Research Council’s (MRC) framework for complex interventions (Craig et 
al, 2008) details a phased approach to implementation. A key message from the MRC 
relates to the importance of investment at the development stage of research, prior to 
large scale evaluations.  To achieve this, existing theory can be supplemented by 
involving key stakeholders in the research process (e.g. the individual/groups targeted 
by intervention). Their involvement in this process can create relevance – factors that 
are grounded in the day-to-day reality of stakeholders’ experiences. Therefore, patient 
and public involvement (PPI) should be considered by researchers in the formulation of 
complex interventions.  
The developing science of PPI is relatively new to clinical psychology. In a recent article 
Rose (2014) discusses the ethical values driving PPI. These values are directly in line 
with the British Psychological Society’s core philosophy (BPS, 2001; e.g. equality, 
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respect, transparency and collaboration). Therefore, PPI involvement in psychotherapy 
intervention research may lead to new insights in treatment formulation and successful 
implementation. 
The literature on PPI suggests involvement in research relates to three stages: 
consultation, collaboration and consumer-led research (e.g. Hewlett et al, 2006). A 
recent systematic review indicates the positive impact of PPI involvement at the early 
stages of research development (Brett et al, 2012). Studies in this review detail the ways 
in which PPI is useful, for example, in developing health research priorities and 
information materials for patients. A relevant message is that PPI at the consultation 
stage can have beneficial outcomes. Thus, the role of stakeholders may be crucial in 
successful implementation of complex interventions, yet this has often been overlooked 
in research (Staniszewska, 2013).  
 
 
Exploration and Consultation 
Qualitative research in the field of schizophrenia has added to scientific understanding 
of the experiential nature of the illness (McCarthy-Jones et al 2013). Furthermore, 
qualitative methodology can provide a robust framework for exploration and discovery.  
 For instance, Waller et al (2013) utilised thematic analysis to explore key stakeholder 
views on their experiences of participating in a pilot of a novel low intensity CBT 
intervention for psychosis. Waller et al conducted semi-structured interviews with both 
staff and service users to investigate the positive/negative factors associated with the 
intervention. An additional factor they explored with the staff group related to the 
feasibility of long-term implementation of the intervention. The emergent themes 
provide constructive insights into the effectiveness of the new intervention and 
highlighted potential barriers for future implementation. Thus, explorative 
methodologies may be an efficient approach to engage with stakeholders in the 
consultation stage of research. 
Furthermore, PPI provides a pragmatic foundation for qualitative research to address 
the identified gap in negative symptom clarity (i.e. lack of key stakeholder opinion) in 
Schooler et al’s study (in press). Therefore, the present study will draw upon the 
methodology used by Waller et al (2013) with a focus on consulting patients and 
family/professional carers to explore their views on negative symptoms and treatment. 
Specifically, the study aims to explore key areas, including: treatment need for negative 
symptoms; the specific negative symptoms that could be targeted; the preferred method 
of intervention; the philosophy underpinning recovery (i.e. CHIME); specific 
implementation issues; and how change will be measured over time.  
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Aims 
To explore client and family/professional carer views on the treatment of negative 
symptoms. Furthermore, an aim would be to explore perceived barriers/facilitators to 
the implementation of a new treatment for negative symptoms.  
Plan of Investigation 
Participants 
Participants will be recruited utilising three separate procedures across the two 
participating sites. 
Inclusion/ Exclusion Criteria  
Inclusion: 
 Adults with a diagnosis of schizophrenia or related psychoses who are exhibiting 
negative symptoms  
 Professional and family/guardianship carers who care for someone who 
experiences negative symptoms 
 Aged 18-65 to fit with referral criteria for Adult Mental Health services.    
Exclusion: 
 Those who may struggle to meaningfully participate due to factors such as 
substance abuse, low cognitive functioning, or capacity and consent issues.  
Recruitment Procedures 
In-patients / Out-patients 
Due to the nature of negative symptoms, an active recruitment procedure which 
reaches out to patients will be followed. Study information will be distributed to 
members of the MDT at both in-patient and out-patient research sites and MDT 
members will be asked to provide details of the study to eligible patients on their 
caseload. The study recruitment information will focus on offering eligible patients the 
chance to find out more about the study from the researcher.  The researcher will be 
available at specific times at both of the sites for people to approach to gain further 
information. Individuals will be given 24 hours to consider their decision to participate. 
If people show an interest they will be invited to take part in the interview process in a 
room at each of the participating sites. Written consent documentation will be collected 
prior to participation. 
Family Carers 
Requests will be made to members of clinical teams to identify people who act as a carer 
for individuals who meet the above ‘patient’ inclusion criteria. Invitation letters to the 
study will be distributed to carers identified by clinical staff. Clinical staff will be asked 
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to obtain consent from carers in order for the researcher to contact them. Additionally, 
the researcher’s contact details will be provided for carers to respond to the invitation. 
If people show an interest they will be invited to attend a local health clinic to 
participate in the interview process. Written consent will be collected prior to 
participation. 
Professional Carers 
Members of the MDT’s at each site will be approached to take part in the interview 
process following the criteria below. This criterion has been set to ensure professional 
carers are working at a level in which they would likely see the impact of negative 
symptoms on therapeutic progress:  
Inclusion: 
 Experience of working in face-to-face therapeutic setting with people who 
experience negative symptoms. 
 Specifically these would include Clinical Psychologists, Nurses, and Allied Health 
Professionals.  
Exclusion: 
 No experience of working with people who experience negative symptoms.  
 Those who do not engage in psychosocial therapeutic work with people who 
experience negative symptoms. 
 
 
Design 
The study will draw upon the methodology previously employed by Waller et al (2013) 
to explore patient and staff perspectives. Specifically, a qualitative design employing a 
semi-structured interview schedule will be used.  
Item Generation for Semi Structured Interviews 
A systematic review of psychosocial treatment of negative symptoms will be analysed 
and the key characteristics will be extracted along the following dimensions: delivery 
format, therapist characteristics, duration, intensity, target processes and symptoms, key 
outcomes, specific implementation issues, methods of monitoring and evaluation, and 
underlying philosophy (e.g. disease/deficit model, the CHIME recovery focus, etc). The 
interview questions and probes will be based on these characteristics. In addition, each 
section of the interview will also include a free-response component. 
Research Procedures 
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Semi-structured interviews will be conducted at both sites with patients, carers and 
staff. These will be audio recorded and transcribed verbatim.  
Data Analysis 
The transcribed interviews will be analysed utilising thematic analysis (Braun & Clarke, 
2006; Boyatzis, 1998). Information from the transcribed data will be coded and used to 
construct themes. Following an inductive (bottom-up) method of reasoning will ensure 
analysis is mainly data-driven (free from researcher biases). Procedures set out by 
Braun and Clarke (2006) will be followed to ensure verification (internal validity) of 
data.  
Justification of Sample Size 
A small sample will be utilised for the semi-structured interviews based on thematic 
analysis guidelines. Thematic analysis can produce a wealth of data but takes 
considerable time to transcribe and analyse. This will be considered in selecting an 
appropriate sample size along with examples from the relevant qualitative literature. 
For instance, Waller et al (2013) interviewed seven staff members and 17 service users.  
 
Settings and Equipment 
An audio recorder will be required for the interviews and an encrypted laptop with 
specific software to allow for transcription. (See Appendix 1).  
Health and Safety Issues 
(See Appendix 2). 
Ethical Issues 
An application will be submitted to the West of Scotland REC. Information sheets will 
detail the study, confidentiality and anonymity. Written consent will be obtained from 
participants with an opt-out option available at no repercussions. Data will be handled 
in line with relevant guidance (e.g. Data Protection Act (1998), Freedom of information 
Act (2000), NHS Confidentiality Code of Practise Guidelines (2003).  Digital data 
(interview recordings) will be stored on NHS encrypted media devices and destroyed 
when the study is finished.  
Financial Issues 
Travel expenses to each site for interviews will be required (this will be through an 
application to the primary researchers’ employing board).  
Timetable  
TBC. 
 
Practical Applications 
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The study will pave the way for future research focussing on a new treatment protocol 
for negative symptoms of schizophrenia. Specifically, the data will form the basis for an 
initial first round Delphi process where a group of experts will be tasked with obtaining 
consensus views on a psychological treatment for negative symptoms. PPI in this study 
allows individuals a chance to provide their own expert knowledge in an area that 
impacts on their daily life. The data will provide key insights into a long term feasibility 
plan for the implementation and scaling up of a new treatment protocol.  
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